BEFORE THE

CITIZENS FINANCIAL ACCOUNTABILITY OVERSIGHT COMMITTEE (CFAOC) ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: METROPOLITAN WATER DISTRICT 700 N. ALAMEDA STREET LOS ANGELES, CALIFORNIA

- DATE: FRI DAY, JANUARY 28, 2011: 2 P. M.
- REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152

BRS FILE NO. : 88990

ΙΝΟΕΧ

I TEM DESCRIPTION NO.	PAGE
OPEN SESSION:	
1. PLEDGE OF ALLEGIANCE.	3
2. OATH OF OFFICE FOR NEWLY APPOINTED CFAOC MEMBER	3
3. CALL TO ORDER AND ROLL CALL.	3
4. OPENING STATEMENT.	4
5. ADOPT MINUTES OF THE JANUARY 26, 2010, CFAOC MEETING.	5
6. PRESENTATION OF THE 2009-10 INDEPENDENT FINANCIAL AUDIT BY MACIAS GINI & O'CONNELL, LLP (MGO), CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE'S (CIRM) AUDIT RESPON AND THE STATE CONTROLLER'S OFFICE AUDIT REV REPORT.	ISE,
7. STATUS UPDATE OF CIRM'S FINANCIAL PERFORMANCE, CURRENT BUDGET, UPDATE OF GRANTS AWARDED, AND GRANT PROCESS.	13
8. PRESENTATION OF CIRM'S "REPORT OF THE EXTERNAL ADVISORY PANEL." CIRM'S RESPONSE TO THE REPORT.	54
9. DISCUSSION OF SB 1064/ALQUIST, CHAPTER 6	37. 53
10. CONSIDERATION OF DRAFT AGENDA FOR NEXT MEETING.	94
11. PUBLIC COMMENT.	NONE
12. BOARD MEMBER TIME.	96
13. ADJOURNMENT.	97
2	

	BARRISTERS' REPORTING SERVICE
1	LOS ANGELES, CALIFORNIA; FRIDAY, JANUARY 28, 2011
2	2 P.M.
3	
4	CHAIRMAN CHIANG: GOOD AFTERNOON. OKAY.
5	WE'LL BEGIN WITH THE PLEDGE OF ALLEGIANCE. IF I CAN
6	ASK EVERYBODY TO RISE.
7	(THE PLEDGE OF ALLEGIANCE.)
8	CHAIRMAN CHIANG: NEXT ITEM IS THE OATH OF
9	OFFICE. WE HAVE A NEW CFAOC MEMBER. I'D LIKE TO
10	WELCOME DR. JAMES KOVACH TO CFAOC. HE WAS JUST
11	APPOINTED BY THE ICOC CHAIR TO REPLACE DR.
12	HOLLANDER.
13	(THE OATH OF OFFICE WAS THEN
14	ADMINISTERED BY THE CONTROLLER.)
15	CHAIRMAN CHIANG: LET ME CALL TO ORDER
16	THIS MEETING AND DO THE ROLL CALL.
17	DANIEL BRUNNER.
18	MEMBER BRUNNER: PRESENT.
19	CHAIRMAN CHIANG: DR. JAMES KOVACH.
20	MEMBER KOVACH: PRESENT.
21	CHAIRMAN CHIANG: DR. LOREN LIPSON.
22	MEMBER LIPSON: PRESENT.
23	CHAIRMAN CHIANG: MR. JIM LOTT.
24	MEMBER LOTT: PRESENT.
25	CHAIRMAN CHIANG: DR. GURBINDER SADANA.
	3

1	MEMBER SADANA: PRESENT.
2	CHAIRMAN CHIANG: WE HAVE A QUORUM.
3	ITEM NO. 4. I WANT TO THANK THE MEMBERS
4	OF THE CITIZENS FINANCIAL ACCOUNTABILITY OVERSIGHT
5	COMMITTEE FOR BEING WITH US THIS AFTERNOON. I KNOW
6	THESE MEETINGS TAKE TIME OUT OF YOUR BUSY SCHEDULES,
7	AND I APPRECIATE YOUR INTEREST AND DEDICATION TO
8	PROTECTING CALIFORNIA'S SIGNIFICANT INVESTMENT IN
9	STEM CELL RESEARCH.
10	WE ARE ALL HERE BECAUSE WE SHARE A
11	COMMITMENT TO ENSURING THAT THE THREE TO \$6 BILLION
12	PLEDGED FOR EMBRYONIC STEM CELL RESEARCH FUNDED BY
13	THE HARD-EARNED DOLLARS OF CALIFORNIA TAXPAYERS IS
14	SPENT LAWFULLY, WISELY, AND SUCCESSFULLY. I AM
15	PROUD OF THE ROLE OF THIS COMMITTEE IN ALL THAT WE
16	HAVE DONE IN PROVIDING THE NECESSARY OVERSIGHT OF
17	THIS INVESTMENT. I ALSO AM VERY PROUD OF THE STEPS
18	WE HAVE TAKEN TO DEMONSTRATE TRANSPARENCY IN THIS
19	AREA OF STATE GOVERNMENT.
20	CALIFORNIANS DESERVE TO KNOW THE FULL
21	STORY OF WHEN AND HOW THEIR TAXPAYER DOLLARS ARE
22	BEING USED, PARTICULARLY WHEN THOSE DOLLARS ARE
23	INVESTED OUTSIDE THE STATE OR EVEN OUTSIDE THE
24	COUNTRY, TO ADVANCE THE SIGNIFICANT AND IMPORTANT
25	RESEARCH.

4

_	
1	WE MEET TODAY MORE THAN SIX YEARS AFTER
2	THE VOTERS' PASSAGE OF PROPOSITION 71 FACING SOME
3	VERY IMPORTANT QUESTIONS ABOUT THIS UNIQUE AND
4	FAR-REACHING PROGRAM. WHAT HAVE WE LEARNED AT THIS
5	STAGE OF THE INSTITUTE'S DEVELOPMENT? HOW CAN OUR
6	DOLLARS BE BETTER SPENT? AND WHAT STEPS SHOULD BE
7	TAKEN TO PLAN FOR THE PROGRAM'S FUTURE?
8	MY COLLEAGUES AND I ARE LOOKING FORWARD TO
9	HEARING RECOMMENDATIONS FROM CIRM'S EXTERNAL REVIEW
10	COMMITTEE ON HOW CIRM SHOULD MOVE FORWARD AND CIRM'S
11	RESPONSE. AND, AGAIN, THANK YOU ALL FOR BEING HERE.
12	I WELCOME ANY INTRODUCTORY REMARKS BY ANY OF THE
13	COMMITTEE MEMBERS. WOULD ANYBODY LIKE TO OFFER ANY
14	THOUGHTS?
15	WE'LL GO TO THE NEXT ITEM WHICH IS TO
16	ADOPT THE TRANSCRIPT OF THE JANUARY 26, 2010, CFAOC
17	MEETING. IS THERE A MOTION?
18	MEMBER LIPSON: SO MOVED.
19	CHAIRMAN CHIANG: WE HAVE A MOTION TO
20	APPROVE. IS THERE A SECOND?
21	MEMBER SADANA: SECOND.
22	CHAIRMAN CHIANG: THERE'S A SECOND. ANY
23	OBJECTION? WITHOUT OBJECTION, THE MOTION PASSES.
24	ITEM NO. 6 IS THE MACIAS, GINI &
25	O'CONNELL, LLP PRESENTS THE INDEPENDENT FINANCIAL
	5

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	AUDIT. MAY I HAVE A REPRESENTATIVE?
2	GOOD AFTERNOON AND PLEASE GIVE YOUR
3	SHARE YOUR NAME FOR THE RECORD.
4	MR. ROBERTSON: MY NAME IS RUSSELL
5	ROBERTSON. I WAS THE MANAGER FROM MACIAS, GINI &
6	O'CONNELL FOR THE FINANCIAL AUDIT OF 2010, THIS
7	PREVIOUS YEAR AUDIT. I ALSO WOULD LIKE TO THANK THE
8	COMMITTEE FOR THE OPPORTUNITY TO PRESENT THE RESULTS
9	OF THAT AUDIT.
10	I WOULD ALSO LIKE TO THANK THE STAFF AND
11	MANAGEMENT OF CIRM DURING THE AUDIT FOR THEIR
12	ASSISTANCE BECAUSE A LOT OF QUESTIONS GO INTO AN
13	AUDIT, SO WE APPRECIATE THEIR TIME AND WILLINGNESS
14	TO PROVIDE THE INFORMATION NEEDED TO PERFORM THE
15	AUDI T.
16	WE WERE ENGAGED TO PERFORM A FINANCIAL
17	AUDIT OF CIRM'S JUNE 30TH, 2010, FINANCIAL
18	STATEMENTS AND ULTIMATELY EXPRESS AN OPINION ON THE
19	FINANCIAL POSITION FOR THAT YEAR ENDED. I DID A
20	PRESENTATION AT THE ICOC MEETING, AND I POINTED OUT
21	AND I THOUGHT IT WOULD BE IMPORTANT TO ALSO POINT IT
22	OUT HERE AS WELL BECAUSE AT THAT MEETING I POINTED
23	OUT THE DIFFERENCE BETWEEN THE AUDITOR, INDEPENDENT
24	AUDITOR, AND THE MANAGEMENT OF CIRM AS FAR AS THE
25	ROLES AND RESPONSIBILITIES GO.

6

1	IN THE INDEPENDENT AUDITOR'S CASE, OUR
2	RESPONSIBILITY IS PLANNING AND PERFORMING THE AUDIT,
3	TO OBTAIN REASONABLE ASSURANCE THAT THE FINANCIAL
4	STATEMENTS ARE FAIRLY STATED IN ALL MATERIAL
5	RESPECTS IN ACCORDANCE WITH UNDERLYING ACCOUNTING
6	PRINCIPLES. WE DO ALSO REVIEW THE INTERNAL CONTROL
7	STRUCTURE OF THE ENTITY; HOWEVER, WE DO NOT EXPRESS
8	OPINION ON INTERNAL CONTROL. THE PURPOSE OF THAT IS
9	BASICALLY TO DESIGN OUR AUDIT PROCEDURES WHEN WE
10	CONDUCT THE AUDIT. HOWEVER, WE DO DO TESTING THAT
11	INVOLVES INTERNAL CONTROL. AND IF THERE IS ANY
12	COMPLIANCE ISSUES, WE DO PRESENT THOSE AS WELL IN
13	OUR REPORT.
14	MANAGEMENT'S RESPONSIBILITIES ARE TO
15	PREPARE THE FINANCIAL STATEMENTS IN ACCORDANCE WITH
16	ACCOUNTING PRINCIPLES AND FOR ESTABLISHING A SYSTEM
17	OF INTERNAL CONTROL TO PREVENT, DETECT ERRORS DURING
18	THE NORMAL COURSE OF BUSINESS. IT IS ALSO
19	MANAGEMENT'S RESPONSIBILITY TO ESTABLISH INTERNAL
20	CONTROLS TO ENSURE COMPLIANCE WITH LAWS,
21	REGULATIONS, CONTRACT PROVISIONS, AND OTHER MATTERS
22	SIGNIFICANT TO THOSE FINANCIAL STATEMENTS.
23	IT'S MY UNDERSTANDING THAT IN YOUR BINDER
24	YOU HAVE BEEN GIVEN THE TWO REPORTS THAT WE ISSUED.
25	ONE IS OUR INDEPENDENT AUDITOR REPORT AND THE OTHER
	7
	1

1	IS THE REPORT TO THE ICOC, WHO IS THE GOVERNING BODY
2	OVER CIRM. SO WE GIVE THEM A REPORT AS WELL.
3	I'M PLEASED TO REPORT THAT WE OBTAINED
4	SUFFICIENT AND APPROPRIATE AUDIT EVIDENCE TO RENDER
5	AN UNQUALIFIED OPINION FOR 2010. AND WHAT
6	UNQUALIFIED OPINION IS, IT'S THE HIGHEST LEVEL
7	ASSURANCE THAT AN INDEPENDENT AUDITOR CAN PROVIDE
8	OVER AN ENTITY'S FINANCIAL STATEMENTS.
9	WE ALSO NOTED IN OUR INDEPENDENT AUDIT
10	REPORT THAT THERE WERE NO MATERIAL OR SIGNIFICANT
11	DEFICIENCIES IN INTERNAL CONTROL. AS I STATED
12	BEFORE, WE DIDN'T OPINE ON INTERNAL CONTROLS, BUT WE
13	DID NOT NOTE ANY DEFICIENCIES IN THAT STRUCTURE FOR
14	THE PAST YEAR.
15	I JUST WANT TO TAKE A BRIEF MOMENT IN THE
16	INDEPENDENT AUDITOR'S REPORT JUST TO POINT OUT SOME
17	AREAS THAT I FEEL ARE IMPORTANT, WHEN YOU DO HAVE A
18	CHANCE TO REVIEW THESE REPORTS, TO KIND OF POINT
19	THESE AREAS OUT OF IMPORTANCE.
20	THE FIRST PART, IT'S IN THE BEGINNING,
21	IT'S CALLED THE MANAGEMENT'S DISCUSSION AND
22	ANALYSIS, AND IT'S PROBABLY THE FIRST SEVEN OR EIGHT
23	PAGES IN THE REPORT. IN THIS AREA, MANAGEMENT HAS
24	PROVIDED SOME FINANCIAL HIGHLIGHTS FOR THE READERS
25	OF THESE FINANCIAL STATEMENTS. AND IT GIVES A HIGH

8

1	LEVEL VIEW OF KIND OF THE OPERATIONS FOR THE YEAR,
2	ANY SIGNIFICANT CHANGES IN THE BALANCES, OR ANY KIND
3	OF ANYTHING THEY THINK IS OF IMPORTANCE TO BRING
4	UP FOR THE FISCAL YEAR.
5	FOLLOWING THAT SECTION ARE THE FINANCIAL
6	STATEMENTS AND THE NOTES TO THOSE FINANCIAL
7	STATEMENTS. AGAIN, I WOULD SUGGEST COMBINING USING
8	THE MANAGEMENT DISCUSSION ANALYSIS AND THE NOTES
9	WHEN YOU DO LOOK AT THESE FINANCIAL STATEMENTS. AND
10	THE FINANCIAL STATEMENTS ARE THREE PAGES. THE OTHER
11	INFORMATION PROVIDED ABOUT THESE FINANCIAL
12	STATEMENTS ARE IMPORTANT BECAUSE IT GIVES MORE
13	DETAIL OF WHAT THESE ACCOUNT BALANCES REALLY
14	REPRESENT. AND ALSO IN THE NOTES IT PROVIDES, NOTE
15	2 IN PARTICULAR, IT PROVIDES WHAT ACCOUNTING
16	POLICIES THAT MANAGEMENT DID FOLLOW. SO IN CASE THE
17	READER WANTED TO KNOW WHAT ACCOUNTING WHAT
18	SIGNIFICANT ACCOUNTING POLICIES WERE USED, THAT ALSO
19	IS PROVIDED THERE.
20	ALSO JUST BRIEFLY, I'D LIKE TO DISCUSS THE
21	OTHER REPORT. IT'S THE REPORT TO THE CITIZENS
22	OVERSIGHT COMMITTEE. AND THIS IS REQUIRED
23	COMMUNICATIONS PER OUR STANDARDS. SO IN THIS REPORT
24	WE WOULD REPORT ANYTHING SIGNIFICANT DURING THE
25	YEAR. FOR EXAMPLE, THERE'S AN AREA IN THERE CALLED
	Q

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

9

1	SIGNIFICANT AUDIT FINDINGS. SO IF THERE WERE ANY
2	AUDIT FINDINGS FOR THE YEAR, YOU WOULD SEE IN THAT
3	SECTION OF THAT REPORT THE AUDIT FINDINGS THAT CAME
4	ABOUT. AND, AGAIN, I'M HAPPY TO SAY THERE WERE NO
5	SIGNIFICANT AUDIT FINDINGS FOR THE FISCAL YEAR 2010.
6	ALSO IN THERE WE DESCRIBE IF THERE'S ANY
7	DIFFICULTIES IN THE AUDIT, ANY MISSTATEMENTS, ANY
8	DISAGREEMENTS. AGAIN, THERE WERE NONE. SO OVERALL
9	A VERY CLEAN AUDIT FOR 2010.
10	THE LAST THING I WANT TO POINT OUT IS WE
11	ALSO WOULD DESCRIBE ANY SIGNIFICANT ESTIMATES THAT
12	WERE USED OR ANY POLICY CHANGES FOR THE YEAR.
13	AGAIN, YOU WILL SEE IN THAT REPORT THAT NO
14	ACCOUNTING POLICIES WERE NO NEW ACCOUNTING
15	POLICIES WERE USED FOR 2010, AND THE ONES THAT WERE
16	IN PLACE, THERE WAS NO CHANGES. SO THAT GIVES A
17	LEVEL OF COMPARABILITY FROM YEAR TO YEAR, SO WE KNOW
18	THAT THEY'RE USING THE SAME POLICIES AND PROCEDURES.
19	I THINK FROM THIS DISCUSSION AND THE
20	OPINION THAT WAS BROUGHT ABOUT, THE MANAGEMENT OF
21	CIRM IS DOING A GOOD JOB OF PREPARING THESE
22	FINANCIAL STATEMENTS AND PROVIDING THE NEEDED
23	INFORMATION FOR THE INDEPENDENT AUDITOR, MYSELF, TO
24	COME IN AND REVIEW. FOR THAT, I'D LIKE TO OPEN IT
25	FOR ANY QUESTIONS.

10

-	
1	CHAIRMAN CHIANG: ANY QUESTIONS BY THE
2	MEMBERS? LET ME ASK A QUESTION. DO YOU ROUTINELY
3	REVIEW THE INTERNAL CONTROLS EVEN THOUGH DO YOU
4	HAVE ANY WRITTEN COMMENTS IN IT FOR ALL AUDITS BY
5	YOUR FIRM?
6	MR. ROBERTSON: YES, WE WILL DOCUMENT THE
7	SYSTEM. FROM A YEAR-TO-YEAR BASIS, WE'LL NOTE ANY
8	CHANGES, ANY NEW PERSONNEL, ANY NEW KIND OF
9	PROCEDURES USED, AND WE'LL ASSESS THOSE.
10	CHAIRMAN CHIANG: VERY GOOD. ARE THERE
11	ANY COMMENTS BY A REPRESENTATIVE FROM THE CIRM ABOUT
12	THE AUDI T?
13	DR. ROBSON: NOT REALLY.
14	MEMBER LOTT: JUST TO BE FAIR, MR.
15	CHAIRMAN. NO MANAGEMENT LETTER?
16	MR. RUSSELL: THE LETTER TO ICOC IS WHAT
17	IS THE REQUIRED COMMUNICATIONS, WHICH REPRESENTS THE
18	MANAGEMENT LETTER, BUT YOU WILL NOTICE THERE'S NO
19	FINDINGS. THERE'S NO WRITE-UPS. YEAH.
20	CHAIRMAN CHIANG: DOES ANYONE WANT TO
21	PROVIDE A RESPONSE?
22	MS. FERGUSON: NO. THE ONLY THING I WOULD
23	LIKE TO ADD IS MARGARET FERGUSON, FINANCE
24	OFFICER, CALIFORNIA INSTITUTE FOR REGENERATIVE
25	MEDICINE. AND WE FOUND NOW I LOST IT. THE ONLY
	11

1	COMMENT I PROBABLY WOULD MAKE WAS THAT WE WORKED
2	DILIGENTLY TO MAINTAIN INTERNAL CONTROLS, TO
3	UNDERSTAND THE ACCOUNTING PROCESSES THAT ARE IN
4	PLACE BECAUSE WE DO CONTRACT OUR ACCOUNTING WITH THE
5	DEPARTMENT OF GENERAL SERVICES, BUT WE KEEP A TIGHT
6	OVERVIEW AND OVERSEE EVERYTHING THAT HAPPENS WITH
7	OUR ACCOUNTS AS WELL AS INTERACTIONS WITH THE
8	CONTROLLER'S OFFICE ON OUR ACCOUNTS. AND WE'RE VERY
9	ATTUNE TO THAT. AND IT'S VERY HIGH PRIORITY TO US.
10	AND I THINK AS THE AUDIT HAS COME OUT CLEAN IS A
11	REFLECTION OF THAT. ANY QUESTIONS?
12	CHAI RMAN CHI ANG: NO.
13	MS. FERGUSON: THANK YOU.
14	CHAIRMAN CHIANG: LET ME INVITE CAROLYN
15	BAEZ FROM MY OFFICE TO PRESENT THE REVIEW OF THE
16	MACIAS FINANCIAL AUDIT.
17	MS. BAEZ: HI. GOOD AFTERNOON. I'M
18	CAROLYN BAEZ, AND I'M AN AUDIT MANAGER WITH THE
19	STATE CONTROLLER'S OFFICE FINANCIAL AUDITS BUREAU.
20	I'M HERE TO PRESENT THE RESULTS OF SCO'S QUALITY
21	CONTROL REVIEW OF MACIAS, GINI & O'CONNELL'S AUDIT
22	OF CIRM FOR THE FISCAL YEAR 2009-10.
23	HEALTH AND SAFETY CODE SECTION 12590
24	REQUIRES THE SCO TO CONDUCT A QUALITY CONTROL REVIEW
25	OF CIRM'S ANNUAL AUDIT AND TO ISSUE A PUBLIC REPORT
	12

1	OF THAT REVIEW.
2	WE COMPARED THE AUDIT WORK PERFORMED BY
3	THE FIRM AS DOCUMENTED IN THE WORKING PAPERS WITH
4	APPLICABLE AUDITING STANDARDS AND REQUIREMENTS,
5	WHICH INCLUDE GOVERNMENT AUDITING STANDARDS,
6	GENERALLY ACCEPTED AUDITING STANDARDS, AND
7	CALIFORNIA BUSINESS AND PROFESSION CODE'S
8	REQUIREMENTS. AND WE DETERMINED THAT THE AUDIT WAS
9	PERFORMED IN ACCORDANCE WITH ALL APPLICABLE AUDITING
10	STANDARDS AND REQUIREMENTS, AND NO DEFICIENCIES WERE
11	NOTED. ANY QUESTIONS?
12	CHAIRMAN CHIANG: VERY GOOD. ARE THERE
13	ANY COMMENTS FROM THE PUBLIC? THANK YOU, CAROLYN.
14	SEEING NONE, NOW WE'LL PROCEED TO THE NEXT
15	ITEM, WHICH IS NO. 7. STATUS UPDATE OF CIRM'S
16	FINANCIAL PERFORMANCE, UPDATE OF THE GRANTS AWARDED
17	AND GRANT PROCESS. LET ME INVITE A REPRESENTATIVE
18	FROM CIRM TO ADDRESS THIS ITEM.
19	AS YOU BRING US UP TO DATE, WE WOULD
20	PARTICULARLY LIKE TO HEAR ABOUT YOUR CURRENT AND
21	PROJECTED BUDGETS AND STATUS OF BOND FUNDING.
22	MS. SILVA-MARTIN: GOOD AFTERNOON, MR.
23	CHAIRMAN, MEMBERS OF THE BOARD. MY NAME IS CHILA
24	SILVA-MARTIN. I'M A FINANCIAL SERVICES OFFICER WITH
25	THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE.

1	I WILL PRESENT THE FINAL OVERVIEW FOR THE 2009-10
2	OPERATING BUDGET AND REPORT ON THE CURRENT YEAR
3	EXPENDITURES THROUGH DECEMBER 31ST.
4	IN YOUR BINDER YOU WILL FIND SOME GRAPHS
5	AND CHARTS WITH SUPPORTING DETAILS AND I
6	APOLOGIZE BECAUSE I DID HAVE A POWERPOINT
7	PRESENTATION, BUT MY FLASH DRIVE ISN'T WORKING IN
8	THE BINDER THAT WE PROVIDED YOU. FIRST THING THAT I
9	WILL COVER ARE THE FINAL EXPENDITURES FOR THE
10	2009-10 FISCAL YEAR.
11	YOU HAVE A GRAPH WITH THREE SETS OF BARS;
12	AND FOR EACH SET OF GRAPHS, THE FIRST BAR, THE BLUE
13	BAR, REPRESENTS OUR ALLOCATION OR OUR BUDGET. THE
14	GREEN BAR REPRESENTS WHAT WE EXPENDED FOR THE
15	2009-10 FISCAL YEAR. AND THE ORANGE BAR REPRESENTS
16	OUR BALANCE AT JUNE 30, 2010.
17	SO LOOKING AT THE FIRST SET OF BARS, WHICH
18	REPRESENTS OUR SALARIES AND WAGES SALARIES AND
19	BENEFITS, EXCUSE ME, WE WERE ALLOCATED A TOTAL OF
20	\$7.4 MILLION FOR SALARIES AND WAGES AND BENEFITS.
21	OF THAT AMOUNT WE SPENT 6,925,000 OR 94 PERCENT OF
22	OUR BUDGET, LEAVING A BALANCE OF \$476,000 OR 6
23	PERCENT.
24	MOVING ON TO OUR OPERATING EXPENDITURES,
25	IN THAT CATEGORY WE WERE ALLOCATED A TOTAL OF
	1 4
	14

1	\$5, 545, 000. WE SPENT \$5, 361, 000, LEAVING A BALANCE
2	OF \$184,000 IN OPERATING EXPENSES. SO OVERALL OUR
3	OVERALL EXPENDITURES, WHICH IS REFLECTED IN THE LAST
4	GROUP OF BARS, WE WERE ALLOCATED \$12,945,000 FOR THE
5	FISCAL YEAR. WE SPENT \$12,286,000, LEAVING A
6	BALANCE OF \$660,000, WHICH IS ROUGHLY ABOUT 5
7	PERCENT.
8	I CAN EITHER TAKE QUESTIONS NOW FOR THE
9	2009-10, OR I CAN MOVE ON TO THE CURRENT YEAR AND
10	THEN TAKE QUESTIONS AT THE END. IT'S UP TO YOU.
11	CHAIRMAN CHIANG: WHY DON'T YOU DO THAT.
12	MS. SILVA-MARTIN: SO THEN MOVING ON TO
13	THE NEXT SET OF GRAPHS. NOW, THERE ARE ACTUALLY TWO
14	GRAPHS FOR THE 2010-11 FISCAL YEAR. AND WHAT WE'VE
15	DONE IS THE FIRST GRAPH REPRESENTS OUR BUDGET FOR A
16	PARTICULAR REPORTING PERIOD. SO IN THIS CASE IT
17	WOULD BE THE BUDGET AND WHAT'S BEEN POSTED TO THE
18	FINANCIAL STATEMENTS FROM JULY 1ST, 2010, THROUGH
19	DECEMBER 31, 2010.
20	AND IT'S THIS CHART RIGHT HERE WITH THE
21	LITTLE SMALL GREEN BARS THAT REPRESENT OUR LAGS.
22	AGAIN, THERE ARE THREE GROUPINGS OF BARS. THE FIRST
23	BAR, THE BLUE BAR, WILL REPRESENT THE AMOUNT THAT
24	WE'VE BEEN ALLOCATED FOR THAT REPORTING PERIOD, AND
25	THE ORANGE BAR REPRESENTS WHAT WE HAVE POSTED TO THE
	16

15

_	
1	FINANCIAL STATEMENTS. AND IN THE CASE OF THE
2	OPERATING EXPENDITURES, THE GREEN BAR REPRESENTS OUR
3	LAGS FOR DECEMBER.
4	SO FOR THE JULY THROUGH DECEMBER REPORTING
5	PERIOD, AS THE FIRST SET OF BARS REPRESENTS FOR
6	SALARIES AND BENEFITS, WE'VE BEEN BUDGETED
7	\$4, 254, 000. WE HAVE SPENT \$3, 841, 000. AND OUR
8	OPERATING EXPENSES, WE WERE ALLOCATED \$2,558,000.
9	WE HAVE POSTED TO THE FINANCIAL STATEMENTS AS OF
10	DECEMBER \$1.6 MILLION, BUT HAVE ABOUT \$700,000 WORTH
11	OF LAGS FOR THOSE INVOICES WHERE WE RECEIVED
12	SERVICES, INVOICES HAVE BEEN RECEIVED, BUT THEY JUST
13	HAVEN'T BEEN POSTED TO THE FINANCIAL STATEMENTS. SO
14	TAKING INTO CONSIDERATION THE LAGS, WE HAVE ACTUALLY
15	EXPENDED ABOUT \$2.3 MILLION OF THE \$2.5 MILLION THAT
16	WE WERE ALLOCATED.
17	SO OVERALL, IN LOOKING AT OUR BUDGET AND
18	LOOKING AT THE LAST SET OF BARS, WE WERE ALLOCATED
19	FOR THIS REPORTING PERIOD \$6.8 MILLION AND HAVE
20	POSTED EXPENDITURES OF A LITTLE BIT UNDER \$6.2
21	MILLION, SO ABOUT 90 PERCENT OF OUR BUDGET.
22	AND THAT BASICALLY CONCLUDES OUR FINANCIAL
23	STATEMENTS. I'M HAPPY TO TAKE ANY QUESTIONS YOU MAY
24	HAVE.
25	CHAIRMAN CHIANG: ANY MEMBERS HAVE ANY
	16
	10

QUESTI ONS?	>
-------------	---

1

MEMBER LIPSON: I HAVE ONE. IT LOOKS LIKE
SALARIES AND BENEFITS HAVE GONE UP CONSIDERABLY IN
THE PAST YEAR; IS THAT CORRECT?

5 MS. SILVA-MARTIN: WE HAD SOME VACANCIES FROM PRIOR YEAR END, AND WE HAVE FILLED SOME OF THE 6 7 VACANCIES IN THE CURRENT YEAR. SO THAT ACCOUNTS FOR 8 SOME OF THE INCREASE IN THE SALARIES AND BENEFITS. 9 AND THE OTHER THING THAT IS CAUSING THE BENEFITS TO 10 GO UP AS WELL IS THAT, AS YOU KNOW, IN GOVERNMENT, WHEN EMPLOYEES FIRST START CIVIL SERVICE, FOR THE 11 FIRST TWO YEARS, THE STATE RETIREMENT IS DIFFERENT 12 13 FOR EMPLOYEES. ONCE THEY HAVE BEEN IN STATE GOVERNMENT FOR MORE THAN TWO YEARS AND THEY VEST 14 INTO THE PERS RETIREMENT SYSTEM, AT THAT TIME THE 15 16 BENEFIT COST TO THE STATE GOES UP, SO SOME OF THAT 17 IS ALSO CAUSING OUR BENEFITS TO GO UP. MEMBER LIPSON: IS THERE A CHANGE IN 18 19 NUMBERS OF PERSONNEL? MS. SILVA-MARTIN: NO. WELL, THAT'S NOT 20 TRUE. IN 2009-10 I BELIEVE WE HAD 47 POSITIONS; IS 21 22 THAT CORRECT, MARGARET? AND IN THIS BUDGET YEAR, WE HAVE 50. BUT AS OF THIS REPORTING PERIOD, WE HAD 45 23 24 POSITIONS FILLED. MEMBER LIPSON: IT LOOKS LIKE IT'S A \$1.4 25

1	MILLION INCREASE. AM I CORRECT?
2	DR. ROBSON: SO I'M JOHN ROBSON. I'M THE
3	VICE PRESIDENT OPERATIONS. JUST THE ONE POINT, I'D
4	LIKE TO GO BACK ON THE RETIREMENT BENEFIT BECAUSE OF
5	THAT 1.4 MILLION, \$400,000 OF THAT IS BECAUSE PEOPLE
6	HAVE WE ARE A NEW ORGANIZATION. SO PEOPLE HAVE
7	BEEN IN THERE FOR TWO YEARS, AND THE SALARY
8	CONTRIBUTION HAS KICKED IN. SO THAT'S A FAIRLY
9	SIGNIFICANT PART OF THAT INCREASE.
10	THE OTHER PART OF THE INCREASE IS RELATED
11	TO PERSONNEL, THAT NEW PERSONNEL WE'VE MOVED UP FROM
12	47 TO 50 POSITIONS. ONE OF THOSE IS THE VICE
13	PRESIDENT FOR RESEARCH AND DEVELOPMENT, AN EXPENSIVE
14	POSITION.
15	MEMBER KOVACH: DO YOU HAVE A NUMBER OF
16	WHAT PERCENTAGE OF SALARY THAT YOUR BENEFITS ARE?
17	DR. ROBSON: IT'S 25.
18	MS. SILVA-MARTIN: IT'S ACTUALLY LOWER
19	THAN THE TYPICAL STATE AGENCY. I THINK WHEN I WAS
20	WORKING AT OTHER STATE AGENCIES, OUR BENEFITS WERE
21	ANYWHERE BETWEEN 35 AND 40, AND HERE IT'S ABOUT 25.
22	BECAUSE OF THAT ONE FACTOR, I THINK THAT IS DRIVING
23	THE NUMBER DOWN.
24	CHAIRMAN CHIANG: WHAT'S THE RETIREMENT
25	FORMULA?
	18

1	MS. SILVA-MARTIN: IT'S THE SAME
2	RETIREMENT AS WHAT OTHER STATE AGENCIES PAY.
3	CHAIRMAN CHIANG: BUT THEY WOULD BE IN
4	CERTAIN CLASSIFICATIONS. WHAT CLASSIFICATIONS ARE
5	THEY IN, SO WHICH TRIGGERS THEIR REQUIREMENT?
6	MS. SILVA-MARTIN: THEY TRIGGER THE
7	RETIREMENT AT THE TWO-YEAR PERIOD. ALL OF OUR
8	POSITIONS DO.
9	CHAIRMAN CHIANG: I JUST WONDERED BECAUSE
10	WE HAVE MULTIPLE JOB CLASSIFICATIONS IN STATE
11	GOVERNMENT. SO THEY HAVE A CERTAIN RETIREMENT
12	FORMULA ATTACHED TO WHAT THEIR CLASSIFICATION IS.
13	MS. SILVA-MARTIN: IT'S 2 PERCENT AT 55.
14	CHAIRMAN CHIANG: CAN YOU ELABORATE A
15	LITTLE BIT MORE ABOUT THE CONTRACTS BUDGET? THE CAP
16	HAS BEEN LIFTED ON THE NUMBER OF EMPLOYEES YOU CAN
17	HAVE. SO WE HAVE STILL SIGNIFICANT CONTRACTS WITH
18	EXTERNAL PARTIES. AND SO I'M TRYING TO GET A SENSE
19	OF WHAT WE EXPECT IN TERMS OF THE SALARIES AND
20	EXTERNAL CONTRACTS.
21	DR. ROBSON: I'LL TRY TO ADDRESS THAT. SO
22	THE CAP WAS JUST LIFTED AS OF JANUARY THE 1ST. SO
23	WE'VE BEEN WORKING UNDER THAT CAP UNTIL THEN. MOST
24	OF THE PEOPLE WHO WE HAVE ON CONTRACT NOW ARE
25	SOFTWARE DEVELOPERS. THIS IS RELATED TO OUR GRANTS
	19

1	MANAGEMENT SYSTEM THAT WE'RE BUILDING. THOSE
2	PEOPLE, I DON'T REALLY FEEL IT WOULD BE APPROPRIATE
3	TO HIRE THEM AS FULL-TIME EMPLOYEES BECAUSE THEY'RE
4	SHORT-TERMERS. WE ONLY EXPECT TO HAVE THEM FOR THE
5	NEXT 18 TO 24 MONTHS. AT THAT POINT WE PROBABLY
6	WILL REPLACE THEM WITH SOME I.T. PEOPLE WHO WOULD BE
7	FULL-TIME STAFF, BUT THEY WOULD NOT BE DEVELOPERS.
8	THEY WOULD BE REALLY INVOLVED WITH MAINTAINING THE
9	SOFTWARE SYSTEMS WE HAVE. THAT'S A LOWER SALARY
10	LEVEL. SO WE WOULD BRING THEM IN AT A LOWER LEVEL.
11	SO THAT'S SOMETHING WE HAVE IN OUR PLANS
12	FOR THE FUTURE, BUT WE DON'T REALLY WANT TO BRING
13	IN WE DON'T WANT TO END THOSE CONTRACTS NOW. I
14	DON'T THINK THAT WOULD BE APPROPRIATE.
15	MEMBER LOTT: MR. CHAIRMAN, ON THAT POINT,
16	IF I MAY. I KNOW YOU HAVEN'T BEEN HERE SINCE THE
17	BEGINNING, BUT THIS HAS BEEN A SIX-YEAR-OLD THIS
18	IS A SIX-YEAR-OLD PROGRAM. WE'RE JUST NOW GETTING
19	TO A GRANTS MANAGEMENT PROGRAM?
20	DR. ROBSON: WELL, THIS IS I CAN GO
21	THROUGH THE HISTORY OF THIS IF YOU LIKE. MOST OF IT
22	PREDATES ME.
23	MEMBER LOTT: IT MIGHT BE HELPFUL TO
24	UNDERSTAND.
25	DR. ROBSON: SO WHEN WE BEGAN, THE FIRST
	20
-	

GRANTS WERE REALLY JUST DONE ON EXCEL SPREADSHEETS
AND PDF FORMS AND PEOPLE SENT THE THINGS IN. WE
KNEW WE HAD TO DEVELOP A SYSTEM THAT WOULD BE A SORT
OF CRADLE-TO-GRAVE SYSTEM SO THAT WE COULD TRACK A
GRANT RIGHT FROM THE INITIATION OF THE RFA THROUGH
THE WHOLE PERIOD OF THE AWARD THROUGH ANNUAL
ACCOUNTING AND THEN EVEN AFTERWARDS TO FOLLOW IT.
MEMBER LOTT: LET ME INTERRUPT YOU AND ASK
THIS QUESTION. I'M SORRY. WE'VE GOT A NUMBER OF
NGO'S, NOT-FOR-PROFIT ORGANIZATIONS, THROUGHOUT THIS
COUNTRY THAT'S GOT THESE THINGS. I GOT TO BELIEVE
THAT YOU CAN GET THESE OFF THE SHELF. WHY ARE WE
BUI LDI NG THI S?
DR. ROBSON: AGAIN, WE HAVE TRIED TWICE
WITH COMMERCIAL PRODUCTS, AND BOTH OF THOSE FAILED.
AND THE REASON THEY FAILED IS BECAUSE WE ARE WE
HAVE BEEN AN EVOLVING ORGANIZATION WITH EVOLVING
PROCESSES AND POLICIES. AND IT HAS JUST NOT BEEN
POSSIBLE TO FIND A SYSTEM THAT COULD KEEP UP WITH
THE CHANGES WE WERE MAKING. WE WOULD CONTINUALLY
HAVE TO BE GOING BACK TO THE VENDOR TO SAY WE NEED
TO MODIFY THIS PART. THAT GETS VERY EXPENSIVE.
AS ART JUST POINTED OUT, WE HAVEN'T BEEN
GIVING OUT GRANTS FOR SIX YEARS. WE'VE BEEN GIVING
THEM OUT FOR FOUR. OUR FIRST GRANTS WENT OUT AT THE
21

21

1	END OF 2006. SO IT HASN'T BEEN QUITE THAT LONG.
2	WE WENT THROUGH AN EXHAUSTIVE PROCESS OVER
3	ABOUT NINE MONTHS TRYING TO EVALUATE WHAT WE SHOULD
4	DO ABOUT OUR GRANTS MANAGEMENT SYSTEM WHEN OUR LAST
5	VENDOR THAT WE WERE WORKING WITH WHEN WE REALIZED
6	THAT SYSTEM WASN'T GOING TO WORK FOR US.
7	I HAVE TO TELL YOU I WAS I AGREE WITH
8	YOU. I THOUGHT WE SHOULD BE ABLE TO FIND SOMETHING
9	THAT WE COULD BRING IN AND ADAPT EASILY TO OUR
10	SYSTEM, BUT WE HAD SOME CONSULTANTS WORK WITH US.
11	THE CONSULTANT THAT I TALKED ABOUT THIS, HE SAID
12	CERTAINLY WE SHOULD BE ABLE TO FIND SOMETHING. BY
13	THE TIME WE WENT THROUGH THE EXERCISE AND LOOKED AT
14	WHAT WE WERE DOING, THE COMPLEXITY OF OUR GRANT
15	APPLICATION PROCESS AND THE TRACKING THAT WE HAVE TO
16	DO, WE ALL AGREED THAT WE REALLY HAD TO DO THIS ON
17	OUR OWN. WE COULDN'T FIND SOMETHING THAT WAS GOING
18	TO BE EFFICIENT AND WOULD WORK WELL FOR US. THERE
19	WERE JUST TOO MANY COMPROMISES THAT WE WERE GOING TO
20	HAVE TO MAKE.
21	MEMBER KOVACH: DID YOU FIND ALSO A LACK
22	OF VENDORS? MEANING IT'S IF I CAN SAY FROM
23	PERSONAL EXPERIENCE AT THE BUCK INSTITUTE, WE HAD
24	SOME OF THE SAME ISSUES IN THE SENSE WE WERE TOO
25	SMALL FOR LIKE AN ORACLE SYSTEM, BUT OTHER COMPANIES

22

1	BASICALLY IT'S A VERY SPECIALIZED AREA.
2	DR. ROBSON: IT'S A SPECIALIZED AREA AND
3	THEY WORK IN THIS PARTICULAR NICHE, AND WE TENDED
4	TO, YOU KNOW, ONE PART OF OUR SYSTEM WOULD WORK WITH
5	THEIRS, BUT OTHER THINGS THAT WE WERE DOING
6	WOULDN' T.
7	WE HAVE USED ONE COMMERCIAL PRODUCT FOR
8	POSTAWARD TRACKING, AND WE'VE BEEN USING THAT. WE
9	WILL PROBABLY EXPAND THAT OR MAYBE EVEN REPLACE THAT
10	AS OUR NEW DATABASE BECOMES COMPLETE, BUT THAT'S A
11	DECISION THAT WE WILL HAVE TO MAKE. WE HAVE USED
12	COMMERCIAL PRODUCTS WHEN WE CAN. AND MOST OF THE
13	UNDERLYING SOFTWARE WE USE IS COMMERCIALLY
14	AVAILABLE. WE'RE NOT DOING THIS FROM SCRATCH.
15	WE'RE BUYING PIECES AND PUTTING THEM TOGETHER AS WE
16	NEED TO, WRITING CODE TO DO THAT EFFECTIVELY.
17	MEMBER LIPSON: WHAT ABOUT THE MONEY SPENT
18	ON OUTSIDE CONTRACTS IN OTHER AREAS, SUCH AS
19	COMMUNICATIONS, WHATEVER THAT'S SUPPOSED TO BE?
20	SINCE YOU HAVE AN OFFICE OF COMMUNICATIONS FOR LEGAL
21	SERVICES WHEN YOU HAVE AN OFFICE OF LEGAL SERVICES?
22	DR. ROBSON: WE HAVE A COMMUNICATIONS
23	OFFICE. IT'S VERY SMALL. WE FEEL THAT WE HAVE A
24	VERY LARGE COMMUNICATIONS MANDATE. WE MAINTAIN OUR
25	OWN WEBSITE. WE DO VIDEOS FOR THAT WEBSITE. WE

1	HAVE A TEAM OF PEOPLE WHO DO THOSE KINDS OF THINGS.
2	WE HAVE OUTSIDE CONTRACTS THROUGH WELL, WE USE
3	THEM FOR A NUMBER OF THINGS. WE HAVE A MANDATE TO
4	PROVIDE SOME EDUCATIONAL SERVICES. SO WE'VE HELPED
5	DEVELOP A CURRICULUM ON STEM CELLS THAT WOULD BE
6	APPLICABLE FOR CALIFORNIA HIGH SCHOOLS. WE HAD A
7	CONSULTANT HELP US, EDUCATIONAL EXPERTS, HELP US
8	DEVELOP THAT. WE FEEL IT'S IMPORTANT.
9	IN FACT, IF YOU READ THE EXTERNAL, THE
10	REPORT FROM THE EXTERNAL REVIEW PANEL, YOU WILL SEE
11	ONE OF THE THINGS THAT THEY EMPHASIZE IS THAT WE
12	SHOULD BE WORKING WITH THE PUBLIC AND WITH PATIENT
13	ADVOCACY GROUPS SO THAT THEY UNDERSTAND EXACTLY WHAT
14	WE'RE DOING. WE'VE HIRED A CONSULTANT TO DO THAT.
15	THIS IS A HUSBAND AND WIFE TEAM, AND THEY REALLY ARE
16	OUR REPRESENTATIVES GOING AROUND THE STATE MEETING
17	WITH PATIENT ADVOCATE GROUPS. WE DON'T HAVE A
18	CAPACITY WITH THE THREE PEOPLE IN THAT OFFICE TO DO
19	EVERYTHI NG.
20	MEMBER LIPSON: NOW YOU'LL BE ABLE TO HIRE
21	PEOPLE.
22	DR. ROBSON: THAT'S A DECISION WE WILL
23	HAVE TO MAKE, WHETHER OR NOT WE SHOULD HIRE
24	FULL-TIME PEOPLE OR HAVE CONSULTANTS WHO WORK ON A
25	PART-TIME BASIS DOING SOME OF THESE THINGS. I THINK
	24

1	THOSE ARE DECISIONS WE'LL MAKE NOW GOING FORWARD,
2	AND WE'LL DO IT BASED ON WHAT'S BEST FOR THE AGENCY,
3	BEST FOR OUR BUDGET.
4	MEMBER LIPSON: WHAT ABOUT THE LEGAL
5	CONTRACTS?
6	DR. ROBSON: THE LEGAL CONTRACTS, THE MAIN
7	LEGAL CONTRACT WE HAVE IS FOR THE LEGAL ADVICE FOR
8	THE BOARD. AND THAT'S BEEN HISTORIC AS LONG AS THE
9	AGENCY BEFORE THE AGENCY BEGAN AS FAR AS I KNOW.
10	MEMBER LIPSON: IS IT NECESSARY TO HAVE
11	THAT BIG A CONTRACT?
12	DR. ROBSON: I GUESS I WOULD DEFER TO THE
13	VICE CHAIR TO SPEAK TO THAT.
14	MR. TORRES: MR. CHAIRMAN AND MEMBERS, ART
15	TORRES, VICE CHAIR OF THE GOVERNING BOARD OF ICOC.
16	ONE OF THE MAIN PRIORITIES IN TERMS OF THE LEGAL
17	REPRESENTATION THE BOARD REQUIRES IS, NO. 1, DEALING
18	INITIALLY WITH MANY OF THE LAWSUITS THAT OCCURRED
19	WHEN THE INITIATIVE FIRST PASSED. THAT REQUIRED
20	EXTENSIVE REVIEW AND EXTENSIVE DEFENSE OF WHERE WE
21	WERE HEADING TO PROTECT THE INITIATIVE'S VALIDITY
22	AND INTEGRITY.
23	IN RESPECT TO THE BOARD ITSELF, MANY OF
24	THE DECISIONS THAT COME BY THE BOARD HAVE TO BE
25	REVIEWED BY COUNSEL TO GIVE THE BOARD AN INDEPENDENT
	25
	20

1	VIEW OF, FOR EXAMPLE, IP REGULATIONS; FOR EXAMPLE,
2	THE IMPACT CERTAIN LEGISLATIVE INITIATIVES MIGHT
3	HAVE ON THAT. I WORK VERY CLOSELY WITH JAMES
4	HARRISON, OUR LEGAL COUNSEL, ON THOSE ISSUES, AS
5	WELL AS DEALING WITH THE CONSTANT REPORTING
6	REQUIREMENTS THAT WE HAVE UNDER THE LAW, WHETHER 700
7	ECONOMIC FORM OR ANY OTHER REPORTING REQUIREMENTS.
8	AND WE'LL TALK ABOUT THAT A LITTLE BIT LATER IN THE
9	PRESENTATI ON.
10	MEMBER KOVACH: THERE'S A REFERENCE TO A
11	6-PERCENT RATIO OF, I BELIEVE, LIKE ADMINISTRATIVE
12	COST.
13	MR. TORRES: YES. IT'S IN THE INITIATIVE.
14	IT'S A 6-PERCENT CAP OF EXPENDITURES. WE CANNOT
15	EXCEED THAT. THAT, THEREFORE, REQUIRES US TO BE
16	VERY VIGILANT IN TERMS OF HOW WE SPEND THE MONEY.
17	MEMBER KOVACH: ARE YOU GOING TO REPORT ON
18	THAT, WHERE YOU ARE WHAT YOUR EXPERIENCE IS
19	RELATING TO THAT?
20	MR. TORRES: OUR EXPERIENCE IS VERY
21	SIMPLE. WE DON'T EXCEED IT.
22	DR. ROBSON: I CAN PROVIDE YOU NUMBERS, IF
23	YOU LIKE. I HAVE THEM WITH ME IF YOU WANT TO SEE
24	THEM.
25	CHAIRMAN CHIANG: IT WAS HINTED IN AN
	27
<u>.</u>	26

1	EARLIER COMMENT THAT MOST OF THE EXTERNAL CONTRACTS
2	INVOLVE I.T., BUT WHEN I'M LOOKING AT THE INTERNAL
3	CONTRACTS FROM THE DOCUMENT FROM THE JUNE 22D, 23D,
4	2010, ICOC MEETING, IT ARTICULATES OR STATES
5	ADVOCACY EDUCATION, COMMUNICATION/MEDIA SERVICES,
6	LEGAL SERVICES, PROFESSIONAL SERVICES, SCIENTIFIC
7	CONSULTING. SO HOW WOULD WE DETERMINE THE I.T.
8	COSTS?
9	DR. ROBSON: I'M SORRY. WHEN YOU ASKED
10	THAT, WE WERE TALKING ABOUT SALARIES, I WAS THINKING
11	IN TERMS OF NUMBERS OF INDIVIDUALS, NOT NECESSARILY
12	ALL CONTRACTS. SO THE CONTRACTORS THAT WE HAVE WHO
13	WORK COME IN AND WORK AT CIRM TO HELP ON THESE
14	PROJECTS, THE BULK OF THEM ARE RELATED TO I.T.
15	THAT'S WHERE I WAS COMING WITH ON THAT.
16	WE CAN WE HAVE INFORMATION THAT
17	SUBDIVIDES. I THINK IT'S IN THE BINDERS. WE HAVE
18	SOME THERE SHOULD BE IN YOUR BINDERS SOME DETAILS
19	THAT SHOW HOW ALL THOSE CONTRACTS ARE DIVIDED UP.
20	CHAIRMAN CHIANG: IS THERE I HAVEN'T
21	HAD A CHANCE TO GO THROUGH IT. DO YOU HAVE THE
22	BUDGET BY FUNCTION?
23	DR. ROBSON: WELL, WE DO BY OFFICE AND BY
24	FUNCTI ON.
25	CHAIRMAN CHIANG: OKAY. IS THAT IN THE
	27

BARRISTERS' REPORTING SERVICE BUDGET INFORMATION? 1 2 DR. ROBSON: YES. YOU HAVE A NUMBER OF 3 DOCUMENTS IN YOUR BINDER. I'M SORRY. CHAIRMAN CHIANG: DON'T APOLOGIZE. AND 4 THEN WE SAW THAT \$649,000 WAS ALLOCATED FOR OTHER 5 OPERATING EXPENSES. CAN I HAVE ADDITIONAL DETAILS 6 7 AS TO WHAT THAT IS? 8 DR. ROBSON: JUST A SECOND. CHILA WILL 9 SPEAK ON THAT. 10 MS. SILVA-MARTIN: SO REALLY FOR OUR OTHER OPERATING EXPENSES, THE BULK OF EXPENDITURES IN THAT 11 AREA ARE FOR SOME OF OUR FURNITURE, GENERAL OFFICE 12 13 SUPPLIES, MINOR EQUIPMENT. WE ALSO HAVE ALL OF OUR MAINTENANCE CONTRACTS UNDER OTHER OPERATING 14 EXPENSES. AND THOSE ARE THE COSTS THAT WE HAVE IN 15 16 THAT OTHER OPERATING EXPENSES. 17 CHAI RMAN CHI ANG: ANYTHI NG ELSE? MS. SILVA-MARTIN: MAINTENANCE FOR LIKE 18 19 OUR PHOTOCOPIERS. 20 CHAIRMAN CHIANG: YOU SAID OFFICE 21 FURNITURE, MAINTENANCE --22 MS. SILVA-MARTIN: GENERAL EXPENSES. 23 CHAIRMAN CHIANG: GENERAL EXPENSES 24 INCLUDE -- \$645,000. 25 MS. SILVA-MARTIN: ONE BIG COST UNDER 28

1	THERE, WE HAVE LIKE OUR BACKUP FOR OUR INFORMATION
2	TECHNOLOGY. WE HAVE SOMEONE WHO PROVIDES I.T.
3	SUPPORT, AND THAT COST COMES OUT OF THAT.
4	CHAIRMAN CHIANG: I.T. SUPPORT. AND WHAT
5	PERCENTAGE OF THE 649,000 WOULD THAT REPRESENT?
6	MS. SILVA-MARTIN: I THINK IT'S ABOUT
7	\$120, 000.
8	CHAIRMAN CHIANG: I'M JUST I JUST DON'T
9	KNOW HOW YOU GET TO 649. IT'S JUST HUGE.
10	MEMBER KOVACH: DO YOU HAVE INTERNAL I.T.
11	PEOPLE THAT YOU CALL NETWORK SUPPORT, OR DO YOU
12	OUTSOURCE ALL THAT?
13	MS. SILVA-MARTIN: ALL OF THAT IS
14	OUTSOURCED.
15	MEMBER LOTT: MR. CHAIRMAN, I'M GOING TO
16	BE JUMPING AHEAD.
17	MS. FERGUSON: IN THAT \$650,000 WE DO HAVE
18	GENERAL EXPENSE, JUST LIKE SHE SAID, WHICH WOULD
19	INCLUDE ALL OUR COMMUNICATION COSTS, IT WOULD
20	INCLUDE ALSO
21	CHAIRMAN CHIANG: SO HOW MUCH ARE THE
22	COMMUNICATION COSTS? JUST A RANGE. 649, YOU
23	SAID
24	MS. FERGUSON: 150,000 OF THE 600,000
25	INCLUDES OUR COMMUNICATION COSTS, INCLUDES ALL OUR
	29
	L /

1	SUPPLIES, INCLUDES MAINTENANCE CONTRACTS, SOME
2	MAINTENANCE CONTRACTS, NOT ALL OF THEM FOR INTERNAL
3	THINGS, AND
4	CHAIRMAN CHIANG: SO MAINTENANCE CONTRACTS
5	FOR WHAT SPECIFICALLY?
6	MS. FERGUSON: ALL OUR COPIERS, ANY
7	REPAIRS THAT WE MIGHT HAVE TO HAVE DONE, ANY MODULAR
8	CHANGES IN OUR FURNITURE OR OFFICE CONFIGURATIONS.
9	THAT'S A HUNDRED FIFTY THOUSAND.
10	MS. SILVA-MARTIN: WHICH ALSO INCLUDES
11	\$250,000 FOR A CHIEF INFORMATION ADVISOR. SO THAT'S
12	A BIG PORTION OF IT THERE.
13	CHAIRMAN CHIANG: YOU ALSO HAVE A CATEGORY
14	FOR INFORMATION TECHNOLOGY. HOW COME THE 250 IS IN
15	THE OTHER VERSUS IN THE INFORMATION?
16	MS. SILVA-MARTIN: BECAUSE WE SEGREGATED
17	THE ACTUAL PROGRAMMING, THE DEVELOPERS FROM THE
18	PERSON WHO'S JUST PROVIDING US WITH OVERSIGHT OVER
19	ALL OF OUR INFORMATION TECHNOLOGY. AND SO THAT'S
20	WHAT WE HAVE IN OUR OPERATING EXPENDITURES, GENERAL
21	OPERATING EXPENDITURES. MAYBE IT'S NOT THE RIGHT
22	CATEGORY TO PUT IT IN AND WE SHOULD MOVE IT UP, AND
23	WE'D BE HAPPY TO DO THAT. BUT WHEN WE DEVELOPED THE
24	BUDGET THIS YEAR, THAT IS WHERE WE PUT IT. SO THAT
25	IS THE BIG BULK OF THAT. THE I.T. SUPPORT, PEOPLE

30

1	WHO PROVIDE EVERYDAY SUPPORT FOR MY COMPUTER'S NOT
2	WORKING, I CAN'T LOG ON, THAT'S ALSO CODED IN THAT
3	GENERAL EXPENSE.
4	MS. FERGUSON: INCLUDED IN THAT 650 AS
5	WELL IS OUR TRAINING, ANY TRAINING THAT WE HAVE, AS
6	WELL AS ANY MEMBERSHIPS THAT WE MAINTAIN.
7	MEMBER KOVACH: MY COMMENT, I GUESS, WOULD
8	BE YOU HAVE ABOUT A BILLION DOLLARS THAT'S BEEN AT
9	LEAST AVAILABLE, AND A MILLION AND A HALF FOR
10	INFORMATION, I WOULD SAY THAT WHEN ONE OF YOUR
11	BIGGEST ASSETS AND CHALLENGES IS IN THE INFORMATION
12	AREA, KEEPING TRACK OF IT AND MAKING SURE THAT IT'S
13	REALLY IN THE KIND OF ENVIRONMENT THAT YOU'RE ABLE
14	TO ACCESS IT. SO I WOULD ADVISE TO ME SEEMS LIKE A
15	REASONABLE AMOUNT, MILLION AND A HALF OVER A
16	BILLION. BUT KEEP YOUR EFFORTS UP TO IT SEEMS
17	LIKE THE ENVIRONMENT IS CHANGING AND WILL CONTINUE
18	TO CHANGE. YOU JUST HAVE TO STAY AFTER IT.
19	MEMBER LOTT: I COULD BE JUMPING AHEAD. I
20	APOLOGIZE IF I AM. STOP ME. THE STRATEGIC PLAN
21	REVIEW, 180 GRANTS FOR THAT. STRATEGIC PLAN REVIEW,
22	CIRM'S STRATEGIC PLAN REVIEW.
23	MR. TORRES: THAT'S COMING NEXT.
24	MEMBER LOTT: WHAT'S THE 180 GRAND FOR?
25	MS. SILVA-MARTIN: JOHN CAN ACTUALLY
	31
	51

1	RESPOND TO THAT, I THINK.
2	DR. ROBSON: SO THAT WAS AN EXTERNAL
3	REVIEW OF THE SCIENTIFIC PROGRAMS AND PROGRESS OF
4	THE ORGANIZATION MEASURED AGAINST THE STRATEGIC AIMS
5	THAT WERE ESTABLISHED IN 2006. IT WAS MANDATED IN
6	THAT STRATEGIC PLAN IN 2006 THAT WE WOULD DO THAT
7	THIS YEAR, AND WE DID THAT IN THE FALL. WE'LL HAVE
8	A REPORT ON THAT.
9	MEMBER LOTT: MY LAST QUESTION, MR.
10	CHAIRMAN, IS ON THE BUDGET FOR THE BOARD. WHAT'S
11	THE 60,000 CONTINGENCY FUND FOR?
12	MS. SILVA-MARTIN: 60,000, WHERE WAS THAT
13	AGAI N?
14	MEMBER LOTT: 60,000 I SAW HERE FOR
15	BUDGET, BOARD ACTIVITY. GOVERNING BOARD
16	CONTINGENCY, 60,000.
17	MS. FERGUSON: I CAN RESPOND TO THAT.
18	MEMBER LOTT: I WATCH THE PENNIES, AND
19	DOLLARS TAKE CARE OF THEMSELVES.
20	MS. FERGUSON: BUT A CONTINGENCY WAS PUT
21	IN THERE BECAUSE THERE WAS GOING TO BE A CHANGE, AS
22	YOU ARE WELL AWARE, OF NEW BOARD MEMBERS COMING ON
23	AND CHANGES IN THE BOARD ITSELF, AND WE WANTED TO
24	ENSURE THAT WE HAD SUFFICIENT FUNDS IN THERE SHOULD
25	WE BE REQUIRED TO DO ANYTHING ADDITIONAL IN TERMS OF
	32

1	MEETING WITH NEW MEMBERS, PROVIDING SERVICES THAT WE
2	DIDN'T ANTICIPATE WITH THIS CHANGE IN THE BOARD. SO
3	WE PUT IN A CERTAIN AMOUNT OF MONEY JUST TO ENSURE
4	THAT WE DIDN'T COME UP SHORT SHOULD WE NEED IT.
5	MEMBER LOTT: ONE LAST, AND THIS IS FOR MY
6	GOOD FRIEND, MR. TORRES. HE'S THE BEST ADVOCATE YOU
7	COULD POSSIBLY HAVE IN YOUR PROGRAM. SO I'M TRYING
8	TO FIGURE OUT WHY 50 GRAND FOR NIELSON MERKSAMER TO
9	DO ADVOCACY FOR YOU. WHAT CAN THEY DO THAT MR.
10	TORRES CAN'T DO FOR YOU?
11	CHAIRMAN CHIANG: THAT'S A GREAT QUESTION.
12	MR. TORRES: THANKS. I'D BE HAPPY TO
13	RESPOND TO THAT. CONSTITUTIONALLY THE VICE CHAIR IS
14	IN CHARGE OF THE RELATIONSHIPS WITH THE NATIONAL AND
15	STATE GOVERNMENT AND LOCAL GOVERNMENTS AS WELL. BUT
16	MANY TIMES THIS DEMOCRAT CAN'T ALWAYS TALK TO
17	CERTAIN REPUBLICANS THAT WE MAY NEED TO EDUCATE
18	ABOUT WHAT'S GOING ON ON THOSE ISSUES. AND THAT'S
19	WHERE NIELSON MERKSAMER
20	MEMBER LOTT: I'M JUST RIPPING YOU, MAN.
21	MR. TORRES: I'M TRYING TO BE DIRECT TO
22	YOU, MR. LOTT. AND I DO NOT INTEND TO BECOME A
23	REGI STERED LOBBYI ST.
24	MEMBER BRUNNER: I HAVE A GENERAL
25	QUESTION. I'M NOT SURE WHO TO DIRECT THIS TO. IF
	33

1	I'M READING THE FINANCIALS CORRECTLY, WE'RE SHOWING
2	A 21-PERCENT INCREASE YEAR OVER YEAR IN THE
3	OPERATING EXPENDITURES. LOOKING OUT NEXT YEAR AND
4	THE YEARS AFTER, WHAT DOES THE TREND LINE LOOK LIKE?
5	DOES THIS KIND OF PEAK AND IT'S GOING TO START TO
6	DROP, OR IS IT LEVELING OFF?
7	DR. ROBSON: SO LET ME START BY ANSWERING
8	A QUESTION THAT DR. KOVACH ASKED A LITTLE EARLIER
9	BECAUSE I THINK IT RELATES TO THIS BECAUSE HE ASKED
10	ABOUT OUR 6-PERCENT ADMINISTRATIVE LIMIT WHICH WE
11	HAVE. THE CHANGE WITH SB 1064 LIFTED THE 50-PERSON
12	CAP, BUT IT LEFT THE 6-PERCENT LIMIT, WHICH IS THE
13	REAL CONTROL. THAT'S THE IMPORTANT ONE IS HOW MUCH
14	MONEY DO WE HAVE AVAILABLE TO SPEND ON
15	ADMINISTRATION. THAT CAP IS A BIT COMPLICATED.
16	ESSENTIALLY WHAT IT MEANS IS WE HAVE \$180
17	MILLION, 6 PERCENT OF 3 BILLION, FOR OUR OVERHEAD
18	FOR OUR ADMINISTRATIVE TO RUN THE ORGANIZATION. AND
19	WE HAVE TO DO THIS IN A WAY THAT WE MEASURE OUR
20	ADMINISTRATIVE COSTS AGAINST THE DISTRIBUTION OF OUR
21	GRANTS. SO WE DON'T WANT OUR ADMINISTRATIVE MONEY
22	TO RUN OUT AND WE STILL HAVE GRANTS TO GIVE, NOR DO
23	WE WANT TO HAVE GRANTS RUN OUT AND WE STILL HAVE
24	MONEY LEFT FOR ADMINISTRATIVE PERSONS. THAT'S NOT
25	LIKELY TO BE THE CASE.

34

1	SO WE HAVE KEPT TRACK OF THIS, AND WE TRY
2	TO MAKE PROJECTIONS ON HOW LONG DO WE EXPECT THESE
3	PROGRAMS TO CONTINUE GOING, AND THEN HOW MUCH MONEY
4	WILL WE NEED FOR ADMINISTRATIVE SERVICES. THERE'S
5	GOING TO BE A POINT, IF THERE'S NOT ADDITIONAL
6	FUNDING THAT COMES AVAILABLE, WHEN WE WILL STOP
7	GIVING OUT NEW GRANTS, BUT WE WILL STILL HAVE GRANTS
8	TO MONITOR AND MAINTAIN. AND AT THAT PERIOD OF
9	TIME, OUR ADMINISTRATIVE COSTS SHOULD START TO FALL
10	BECAUSE WE WON'T NEED AS MANY PERSONNEL, WE WON'T
11	NEED AS MANY CONTRACTS, ETC., ETC.
12	AND SO THE IDEA IS TO HAVE THOSE TWO
13	THINGS COME DOWN AT THE SAME TIME. SO WE KEEP VERY
14	CLOSE TRACK ON THESE. AND JIM'S QUESTION WAS WHERE
15	ARE WE IN THAT 6 PERCENT, HOW MUCH HAVE WE SPENT.
16	WE HAVE SPENT ABOUT, AT THE END OF THIS FISCAL YEAR,
17	I THINK WE'LL BE AT ABOUT 40 MILLION OF THE 140
18	OF THE 180. AND SO THAT'S WHAT WE HAVE REMAINING.
19	NOW, WHAT WE ANTICIPATE, WHEN WE LOOKED AT
20	MODELING OUR EMPLOYEES, WHAT WE THOUGHT WE COULD
21	ACCOMMODATE IN TERMS OF OUR OFFICE SPACE AND THEN
22	ALSO THIS 6-PERCENT BUDGET LIMIT IS THAT WE COULD
23	BUILD UP TO ABOUT 60 EMPLOYEES OR THE EQUIVALENT OF
24	60 EMPLOYEES AND A COUPLE OF CONTRACTORS IF WE STILL
25	HAVE SOME SOFTWARE DEVELOPERS WORKING WITH US. AND

35

1	WE COULD MAINTAIN THAT 60 PROBABLY UNTIL ABOUT 2016
2	OR SO. AT THAT POINT OUR GRANT ACTIVITY WOULD START
3	TO DECLINE, AT LEAST THE WORK IN GETTING PREPARED TO
4	ISSUE NEW GRANTS WOULD START TO DECLINE, AND THEN
5	THOSE NUMBERS WOULD THEN START TO DECLINE.
6	I WOULD SAY THIS BUDGET IS LIKELY TO RISE
7	FOR THE NEXT YEAR OR TWO, AND THEN IT PROBABLY WILL
8	FLATTEN OFF OTHER THAN INFLATIONARY KINDS OF THINGS,
9	AND THEN IT SHOULD START TO GO DOWN IN ABOUT 2015 OR
10	S0.
11	MEMBER BRUNNER: THANK YOU. JUST SO I
12	UNDERSTAND IT, I KNOW THERE'S A 6-PERCENT CAP. BUT
13	TO THE EXTENT YOU ARE BELOW THE 6 PERCENT, WHAT
14	HAPPENS TO THAT MONEY? IS THAT AVAILABLE FOR
15	GRANTS?
16	DR. ROBSON: IT WOULD BE.
17	MEMBER BRUNNER: SO THE IDEA WOULD BE TO
18	RUN IT AS EFFICIENTLY AS POSSIBLE. PURPOSE OF THE
19	PROGRAM IS NOT ADMINISTRATION; IT'S TO GET GRANT
20	MONEY OUT THE DOOR.
21	DR. ROBSON: ABSOLUTELY. WE DO RUN, I
22	THINK, AN EFFICIENT ORGANIZATION COMPARED TO OTHER
23	ORGANIZATIONS THAT HANDLE GRANTS AND BUDGETS OF OUR
24	SIZE. I THINK WE'RE WELL UNDER WHAT IS THE NATIONAL
25	AVERAGE.
	24
	36

1	MEMBER KOVACH: ANOTHER PURPOSE IS TO
2	CREATE THERAPIES THAT ARE TAKEN UP BY BUSINESSES.
3	SO AS TIME MOVES FORWARD, I CAN UNDERSTAND THE BASIC
4	RESEARCH BEING REDUCED, BUT THEN THE INTELLECTUAL
5	PROPERTY COULD INCREASE. DO YOU INTEND TO RELY ON
6	BASICALLY KIND OF THE MARKET ESSENTIALLY TO DO THAT,
7	OR ARE YOU GOING TO ACTUALLY HAVE SOME INDIVIDUALS
8	THAT YOU HIRE THAT ACTUALLY PUSH THAT TECHNOLOGY
9	OUT?
10	DR. ROBSON: THAT'S A COMPLICATED
11	QUESTION. I'LL GIVE A SHOT AT IT, AND PERHAPS ALAN
12	TROUNSON WOULD LIKE TO TALK ABOUT THAT AS WELL.
13	SO FIRST OF ALL, WE DON'T ANTICIPATE THAT
14	WE WOULD EVER STOP FUNDING BASIC RESEARCH. THAT'S
15	ALWAYS GOING TO BE AN ENGINE FOR THIS PROGRAM AND
16	FOR STEM CELL RESEARCH ONCE THIS ORGANIZATION NO
17	LONGER EXISTS, ASSUMING WE DON'T GET ADDITIONAL
18	MONEY. WE ARE STARTING TO SHIFT OUR EMPHASIS. IF
19	YOU DO READ THE EXTERNAL REVIEW, THE REPORT WHICH
20	YOU'LL HEAR ABOUT IN A MINUTE, YOU WILL SEE THAT
21	THEY EMPHASIZE THESE ISSUES, THAT WE NEED TO NOW
22	THAT WE'VE GONE THROUGH SORT OF OUR START-UP PHASE,
23	WE NEED TO START SHIFTING OUR FOCUS AND OUR EMPHASIS
24	ON TRANSLATION AND CLINICAL ISSUES. AND THAT'S
25	COMPLICATED. IT INVOLVES REGULATORY AGENCIES, IT

37

1	INVOLVES THE PRIVATE SECTOR, SO FORTH.
2	NOW, IF YOU WERE REFERRING TO MONEY THAT
3	MIGHT BE CREATED DUE TO SOME COMPANY DEVELOPING A
4	PRODUCT THAT IS A BIG HIT AND THAT WE'VE HELPED
5	SUPPORT, IF THAT HAS BEEN SUPPORTED THROUGH A GRANT
6	AND THERE ARE ROYALTIES THAT COME, WE DO HAVE A
7	POLICY THAT WE WILL GET SOME OF THOSE ROYALTIES
8	BACK. THEY DON'T COME TO CIRM. THEY GO DIRECTLY TO
9	THE GENERAL FUND.
10	WE ALSO HAVE A PROGRAM WHERE WE GIVE OUT
11	LOANS. THAT IS REALLY WE'VE HAD A LITTLE TROUBLE
12	KIND OF GETTING TRACTION WITH THAT. WE HAVE ONE
13	LOAN OUT NOW AND WE HAVE ANOTHER ONE WE HOPE TO
14	FINALIZE IN FEBRUARY. THE RETURN ON THE LOAN, THAT
15	IS, THE REPAYMENT OF THE LOAN, AND THESE LOANS
16	THE ONE WE HAVE OUT RIGHT NOW COMES WITH A CERTAIN
17	PERCENTAGE OF WARRANTS. IF THERE'S MONEY THROUGH
18	THE WARRANTS OR THROUGH THE REPAYMENT OF THE LOAN,
19	THAT DOES COME BACK TO CIRM AND THAT WOULD BE
20	RECYCLED.
21	JUST BECAUSE OF THE QUESTION THAT CAME UP
22	ABOUT ADMINISTRATIVE VERSUS, THAT MONEY COULD BE
23	RECYCLED, BUT RECYCLED FOR GRANTS OR FOR SOME
24	SERVICES RELATED TO THE BONDS, BUT NOT FOR GENERAL
25	ADMI NI STRATI ON.

38

1	MEMBER LOTT: PR, TALK TO ME ABOUT PR.
2	I'M TRYING TO FIGURE OUT. YOU GOT A MONOPOLY ON THE
3	MARKET HERE. GOVERNMENT AGENCY, QUASI GOVERNMENT
4	AGENCY, HOWEVER YOU WANT TO CLASSIFY IT, WHAT ARE
5	YOU SPENDING PR MONEY TO DO?
6	DR. ROBSON: WE DO IT AS EDUCATION.
7	MEMBER LOTT: EDUCATION FOR WHOM?
8	DR. ROBSON: FOR THE PUBLIC. WE FEEL IT'S
9	PART OF OUR OBLIGATION AS A STATE AGENCY TO INFORM
10	PEOPLE WHAT'S HAPPENING WITH THEIR MONEY.
11	MEMBER LOTT: AND YOU NEED TO HAVE A PR,
12	AN EXTERNAL PR FIRM TO GET OUT EDUCATIONAL MATERIAL?
13	DR. ROBSON: THEY PROVIDE US THAT'S
14	FLEISHMAN. PRIMARILY WHAT THEY DO WELL, THEY DO
15	A COUPLE OF THINGS. THEY PROVIDE US WHAT WE CALL
16	OUR CLIP SERVICE THEY SEND US. DAILY WE GET THEY
17	PROVIDE NEWS FROM AROUND THE WORLD.
18	MEMBER LOTT: I KNOW THAT. THAT DOESN'T
19	COST 125, 000.
20	DR. ROBSON: NO. NO. THAT DOESN'T.
21	MEMBER LOTT: SO I'M TRYING TO FIGURE OUT
22	WHAT TYPE OF SPIN YOU'VE GOT TO USE TO EDUCATE THE
23	PUBLIC. THAT'S WHAT PR FIRMS DO. THEY PUT A SPIN
24	ON IT.
25	DR. TROUNSON: I THINK THE TEAM ARE DOING
	39

1	PERFECTLY WELL IN ANSWERING YOUR QUESTIONS. IN THE
2	AREA OF THE PUBLIC RELATIONS, THIS IS AN UNUSUAL
3	ORGANIZATION. IT WAS BUILT ON SOME VERY STRONG
4	CRITICISM FROM CERTAIN SECTORS IN THE COMMUNITY, AND
5	THERE REMAINS A VERY STRONG UNDERFLOW OF NEGATIVITY.
6	IF YOU READ DOWN INTO THAT LITERATURE, IF YOU EVER
7	GO DOWN THERE, YOU FIND THAT IT'S A VERY STRONG
8	NEGATIVE FLOW. SO THAT BURSTS OUT EVERY NOW AND
9	AGAIN, AND IT'S SOMETHING THAT WE TRY AND GET SOME
10	MORE PROFESSIONAL ADVICE ON FROM TIME TO TIME.
11	AND THAT MAY BE RELATED TO ACTIVITIES IN
12	THE COURTS WHERE EMBRYONIC STEM CELLS JUST RECENTLY
13	HAVE BEEN FOUND TO NOT BE INTERPRETED AS BEING
14	APPROPRIATE FOR FEDERAL GOVERNMENT FUNDING. WHAT
15	SHOULD OUR RESPONSE BE TO THAT? BECAUSE WE ARE
16	CONCERNED THAT WHAT WE SHOULD HAVE IS REASONABLE
17	RESPONSES TO THESE KIND OF THINGS. SO IN THE SENSE
18	THAT THERE'S BEEN A PUBLIC RELATIONS FIRM, THEY HAVE
19	BEEN TRYING TO HELP US DO THE RIGHT THING AND MAKE
20	SURE THE STATE AGENCY WITHIN THE CALIFORNIA STATE IS
21	BEING POSITIONED IN A REASONABLE FRAME.
22	AND THERE IS A CONTINUOUS STREAM OF ADVICE
23	ABOUT WHETHER WE SHOULD DO SOMETHING WHEN ARTICLES
24	APPEAR, EITHER IN NEWSPAPERS OR IN OTHER STATES OR
25	IN THE FEDERAL SPHERE OR EVEN IN THE STATE, SHOULD
	10

40

1	WE BE RESPONSIVE TO THAT OR SHOULD WE JUST MARCH ON
2	WITH OUR SCIENCE? I THINK THERE'S PART OF I
3	THINK SOME QUESTIONS MIGHT HAVE BEEN ASKED LAST
4	YEAR. THE IMPORTANT PART IS TO MAKE SURE THE
5	COMMUNITY FEELS VERY SUPPORTIVE ABOUT THIS
6	ORGANIZATION. SO WE NEED TO BE CAREFUL ABOUT IT,
7	KNOWING THAT IT DOES HAVE THIS SORT OF STRONG
8	UNDERCURRENT THAT GOES BACK A LONG TIME
9	HI STORI CALLY.
10	MEMBER LOTT: HOW WOULD THAT PAIR THEN OR
11	MATCH WITH COMMUNITY OUTREACH? YOU'VE GOT A
12	SEPARATE LINE ITEM FOR THAT.
13	DR. TROUNSON: WELL, THE COMMUNITY
14	OUTREACH IS MORE FOR THE PATIENT ADVOCACY TYPE OF
15	ACTIVITIES. THAT IS, TO REPORT THE SCIENCE
16	PROCESSES MORE INTO THE PATIENT ADVOCACY SYSTEMS,
17	INTO THE HIGH SCHOOLS. WE SUPPORT SCIENTISTS GOING,
18	PARTICULARLY GRANTEES, GOING OFF TO GIVE TALKS TO
19	HIGH SCHOOL GROUPS, CHURCH GROUPS, WHATEVER. WE DO
20	A LOT OF THAT OURSELVES AS WELL. SO COMMUNITY
21	OUTREACH IS TO TRY AND PROVIDE FROM OUR BASIC FLOOR
22	THE INFORMATION WHICH IS MUCH MORE LOCALIZED.
23	MEMBER LOTT: ONE GENERAL QUESTION, MR.
24	CHAIRMAN. ALL OF OUR QUESTIONS ARE FOCUSING ON ONE
25	POINT, AND THAT IS THAT WE HAVE A VAST AND
	41

1	WELL-DEVELOPED STATE GOVERNMENT INFRASTRUCTURE. AND
2	IT WOULD SEEM TO ME THAT WE MAY NOT BE TAKING FULL
3	ADVANTAGE OF THE SERVICES THAT WE HAVE WITHIN
4	GOVERNMENT TO BE ABLE TO ACCOMPLISH A LOT OF WHAT IT
5	IS I'M SEEING HERE IN EXTERNAL RELATIONSHIPS.
6	DR. TROUNSON: OKAY. SO I THINK THAT'S
7	ALSO PART OF THE EXTERNAL REVIEW REPORTED TO US ON
8	COMMUNICATIONS, SAVING ESSENTIALLY THE CABBY IN THE
9	STREET OUGHT TO BE VERY WELL AWARE OF CIRM BECAUSE
10	IT'S A BIG INVESTMENT BY THE STATE, AND THEY SHOULD
11	HAVE A VERY GOOD KNOWLEDGE OF WHAT WE'RE DOING. SO
12	OUR COMMUNICATIONS NEED TO BE EVEN MORE EFFECTIVE.
13	MEMBER LOTT: I'M JUST ASKING THE QUESTION
14	WHY ARE WE SPENDING SO MUCH DEALING WITH OUTSIDE
15	ENTITIES, PURCHASING SERVICES FROM OUTSIDE ENTITIES,
16	WHEN WE'VE GOT THIS VAST STATE INFRASTRUCTURE WITH A
17	HUGE AMOUNT OF TALENT THAT WE'RE ALREADY PAYING FOR
18	AS TAXPAYERS. I'M TRYING TO FIGURE OUT WHY YOU'RE
19	GOING SO MUCH, ALL THESE EXTERNAL LEGAL SERVICES
20	COST THAT WAS ENUMERATED EARLIER, WHAT I JUST GOT
21	THROUGH ASKING. WHY ARE WE NOT USING THE STATE
22	GOVERNMENT MORE?
23	DR. TROUNSON: WE ARE USING THEM AS MUCH
24	AS WE CAN. WE DO APPROACH OTHER STATE AGENCIES,
25	SISTER AGENCIES TO ASSIST WHERE IT'S APPROPRIATE.
	42

1	MEMBER LOTT: WHY CAN'T THE DOJ, WHY CAN'T
2	THE DOJ DO A LOT OF WHAT YOU ARE ASKING THOSE
3	EXTERNAL LAWYERS TO DO?
4	DR. TROUNSON: WELL, MAYBE I'LL ASK
5	SENATOR TORRES TO RESPOND TO THAT BECAUSE THAT'S A
6	REASONED QUESTION, BUT MAYBE HE WOULD GIVE A BETTER
7	ANSWER THAN I WOULD.
8	MEMBER KOVACH: DOES THAT MEAN DEPARTMENT
9	OF JUSTICE?
10	MEMBER LOTT: YES, SIR. ATTORNEY
11	GENERAL'S OFFICE.
12	MR. TORRES: THE ATTORNEY GENERAL'S OFFICE
13	HAS OVER 65,000 ACTIVE CASES RIGHT NOW. THEY ARE
14	BURDENED AS THEY ARE ALREADY. ANY OTHER LAWYER,
15	WHETHER THEY'RE GENERAL SERVICES OR THE DEPARTMENT
16	OF HEALTH, AREN'T AVAILABLE TO US BECAUSE OF THEIR
17	OWN TREMENDOUSLY STRAPPED OPERATIONS.
18	BUT SPEAKING TO YOUR POINT SPECIFICALLY,
19	ONE OF THE RECOMMENDATIONS THAT CAME FROM THE
20	EXTERNAL REVIEW, AND DR. ROBSON REVEALED THIS
21	REORGANIZATION BASED UPON HIS OWN EVALUATION AND
22	WHERE HE THINKS THE AGENCY SHOULD MOVE TO THE BOARD
23	YESTERDAY IN SAN FRANCISCO AND APPROVED BY THE
24	BOARD, AND HE PRESENTED THAT TO THE STAFF THIS
25	MORNING. DR. TROUNSON DID, YES, TO THE BOARD AND TO

43

1	THE STAFF, INDICATING THAT WE NEED TO REORGANIZE.
2	AND PART OF THAT REORGANIZATION IS LESS RELIANCE ON
3	EXTERNAL PR PEOPLE, FOR EXAMPLE. BECAUSE THERE WILL
4	BE AN EFFECTIVE, I THINK, WHAT HE HAS RECOMMENDED AN
5	EFFECTIVE DIVISION BETWEEN SCIENCE COMMUNICATIONS
6	AND COMMUNICATIONS FOR THE AGENCY AS A WHOLE, TO
7	PATIENT ADVOCATES THAT HE INDICATED, THE OUTREACH
8	THAT WE HAVE, BUT ALSO TO GET AN INTERNAL PERSON
9	RATHER THAN RELYING ON A PUBLIC RELATIONS FIRM TO
10	ESTABLISH THAT.
11	AND WHAT THEY HAVE RECOMMENDED, DR.
12	TROUNSON AND MR. KLEIN IN CONJUNCTION AND APPROVED
13	BY THE BOARD YESTERDAY, WAS SPECIFICALLY TO HAVE THE
14	VICE CHAIR INTERFACE WITH THAT NEW PERSON THAT WE
15	ARE ABOUT TO HIRE FOR COMMUNICATIONS THAT WILL GIVE
16	US LESS RELIANCE ON THE PR FIRM. I'M NOT HAPPY WITH
17	WHAT'S BEEN UTILIZED AT THIS POINT.
18	THE OTHER THING ON THE CAP, REMOVING THE
19	CAP ALSO ALLOWS US TO DIMINISH THE AMOUNT OF EFFORT
20	THAT WE RELY UPON EXTERNAL CONSULTANTS. SO AS WE
21	MOVE FORWARD IN A VERY DIFFICULT PHASE WITH HUMAN
22	TRIALS COMING UP VERY QUICKLY, SOME ALREADY ARE
23	OPERATIONAL, IS TO MAKE SURE THAT WE HAVE INTERNAL
24	CONTROLS OF OUR COMMUNICATIONS EFFORT RATHER THAN
25	RELYING ON A PR FIRM THAT MAY NOT REALLY HAVE ALL OF

44

1	OUR BEST INTERESTS IN MIND AND REALLY DOESN'T KNOW,
2	FOR THE MOST PART, JUST HOW TO FASHION THE MESSAGE.
3	SO LEEZA GIBBONS, WHO'S ON OUR BOARD,
4	SHERRY LANSING, WHO'S ON OUR BOARD, MYSELF, ARE PART
5	OF A COMMUNICATIONS SUBCOMMITTEE THAT WILL BE
6	LOOKING AT THIS OPERATION ONCE WE HIRE THIS PERSON.
7	I'LL WORK VERY CLOSELY WITH THEM AND UTILIZE THE
8	EFFORTS, AS YOU SAID, WHY AREN'T WE UTILIZING. HERE
9	WE HAVE TWO INCREDIBLE PEOPLE FROM THE MEDIA, LEEZA
10	AND SHERRY, TO BE USED AS VALUABLE TOOLS FOR AN
11	AGENDA. I'M LOOKING FORWARD TO DOING THAT.
12	CHAIRMAN CHIANG: I THINK THAT'S VERY
13	I MPORTANT.
14	I JUST, ALAN, WITH ALL DUE RESPECT, I
15	DON'T SEE SPENDING \$125,000 TO RESPOND TO A BUNCH OF
16	ARTICLES BY PEOPLE WHO AREN'T SUPPORTIVE OF
17	EMBRYONIC STEM CELL RESEARCH. I MAY BE MISSING
18	SOMETHING. MAYBE THERE'S INTENSITY, BUT THAT'S BEEN
19	IN EXISTENCE FOR A WHILE. AND THERE OUGHT TO BE
20	EFFICIENCIES AND, FRANKLY, IT'S NOT LIKE WE'RE
21	CREATING NEW MESSAGES EVERY TIME THEY COME UP. SO
22	THE ARGUMENTS ARE PRETTY STANDARD.
23	DR. TROUNSON: I TAKE YOUR POINT, CHAIR,
24	AND WE'LL TAKE THAT BACK TO REVIEW IT. AS SENATOR
25	TORRES SAYS, THAT THERE IS GOING TO BE A
	45

1	READJUSTMENT IN THIS AREA OF COMMUNICATION. WE'RE
2	ALL VERY KEEN TO MAKE IT MORE EFFECTIVE FOR THE
3	COMMUNITY BROADLY. I JUST WANTED FOR YOU TO KNOW
4	THAT EVERY DAY YOU WALK INTO OUR OFFICE, THERE'S
5	SOMETHING THAT YOU REALLY HAVE TO VERY OFTEN
6	EVERY DAY YOU HAVE TO LOOK AT SOME ARTICLE AND
7	DECIDE WHETHER YOU WANT TO ADDRESS IT OR NOT. HOW
8	DO YOU POSITION YOURSELF TO AT LEAST MAKE THE
9	COMMUNITY FEEL THAT WE'RE RESPONSIVE? BUT WE'RE NOT
10	BEING RESPONSIVE TO ABSOLUTELY EVERYTHING THAT'S OUT
11	THERE BECAUSE IT'S PRETTY CONTINUAL.
12	CHAIRMAN CHIANG: THERE WAS REFERENCE
13	EARLIER TO THE GRANTS. THE FACT THAT THE GOVERNOR
14	IS NOT PLANNING ON SELLING ANY BONDS NOW, HOW IS
15	THAT GOING TO IMPACT GRANTS?
16	DR. TROUNSON: THAT WON'T AFFECT ANY OF
17	THE GRANTS UP UNTIL THE MIDDLE OF NEXT YEAR. I'VE
18	HAD DR. ROBSON TAKE A VERY CLOSE LOOK AT THE
19	EXPENDITURE AND COMMITMENT. AND REALLY BY JUNE,
20	JULY NEXT YEAR WE'LL BE REALLY NEEDING TO LOOK AT
21	HAVING ADDITIONAL FUNDS. SO THE FIRST SIX MONTHS
22	WON'T AFFECT US NOT BEING ABLE TO SELL BONDS IN THIS
23	FIRST SIX MONTHS, BUT IN THE SECOND SIX MONTHS OR
24	INTO SOMETIME NEXT YEAR IT MAY.
25	CHAIRMAN CHIANG: IF I CAN INTERJECT, I'M
	46

1	TRYING TO GET A LITTLE BIT MORE DETAIL. TO WHAT
2	EXTENT DO YOU THINK IT'S GOING TO IMPACT US?
3	DR. TROUNSON: I DON'T THINK IT'S GOING TO
4	IMPACT AT ALL AT THIS STAGE AT ALL FOR THE SIX
5	MONTHS, NONE AT ALL.
6	CHAIRMAN CHIANG: OKAY. VERY GOOD.
7	THINKING ABOUT THE LOANS, OBVIOUSLY
8	THERE'S GOING TO BE A CERTAIN RETURN TO CIRM. I'M
9	TRYING TO GET A BREAKDOWN. OBVIOUSLY WE'RE TRYING
10	TO PROTECT THE TAXPAYERS' INTEREST HERE TOO. I WANT
11	TO GET A DEEPER SENSE OF THE VIEWS ON THE LOANS IN
12	FROM PRIVATE INDUSTRY.
13	DR. TROUNSON: THERE'S BEEN 380 PROJECTS
14	AWARDED AND THERE'S ONE LOAN. IT'S ONE LOAN IN ONE
15	OF THE MAJOR GRANTS, ONE OF THE ONES THAT WAS WORTH
16	\$20 MILLION. SO THAT'S SUBSTANTIVE IN ITSELF, BY
17	ITSELF, BUT IT IS EXTREMELY SMALL IN TERMS OF THE
18	NUMERI CAL COMPONENT.
19	THE IMPORTANT PART, WE HOPE, IS
20	ADJUSTMENTS JUST MADE YESTERDAY REALLY BY THE BOARD
21	TO MAKE THOSE LOANS MORE ATTRACTIVE TO THE BUSINESS
22	SECTOR. YOU MIGHT APPRECIATE THAT EVERY TIME YOU
23	HAVE AN INTERACTION WITH THE PRIVATE SECTOR, IT'S
24	OFTEN A NEGOTIATION, BUT VERY FREQUENTLY IT'S OVER
25	SOME COMPONENT PART THAT A CHIEF FINANCIAL OFFICER

47

1	IN THAT ORGANIZATION WILL FIND UNACCEPTABLE. BUT I
2	THINK WE HAVE AS CLOSE AS WE CAN GET AT THE PRESENT
3	TIME, WITH REMOVAL OF THE WARRANTS, OPPORTUNITIES
4	FOR BRINGING IN THE PRIVATE SECTOR.
5	AND WE'RE ABOUT TO REVIEW THE MOST
6	ADVANCED GRANTS. THOSE ARE GRANTS THAT ARE ALREADY
7	IN THE CLINIC OR ALREADY HAVE WHAT IS CALLED AN IND,
8	A REGISTRATION FOR A CLINICAL TRIAL. AND IN THOSE
9	STUDIES, THERE ARE FOUR. THOSE FOUR STUDIES INVOLVE
10	COMPANIES AS THE PRIMARY COMPONENTS. THEY WILL ALL
11	INVOLVE LOANS. THOSE LOANS WILL RETURN THE MONEY
12	PLUS AN INTEREST RATE TO THE INSTITUTE.
13	CHAIRMAN CHIANG: SORRY TO INTERRUPT. I'M
14	INTERESTED IN THE TERMS. I UNDERSTAND YOU WANT TO
15	ASSIST BUSINESS, BUT OFTENTIMES, AS I SAW WITH WHAT
16	HAPPENED A COUPLE YEARS AGO ON WALL STREET, THE
17	TERMS WALL STREET WILL CHARGE GOVERNMENT ARE TERMS
18	THAT WALL STREET ITSELF I'M NOT TRYING TO BE
19	PEJORATIVE ABOUT ALL OF WALL STREET BUT TERMS
20	THEY WON'T ACCEPT THEMSELVES.
21	SO MY INTEREST HERE IS TO MAKE SURE THAT
22	CIRM DOES WELL, THE TAXPAYERS DO WELL. IT'S NOT OUR
23	JOB TO PROVIDE SUBSIDIES. THAT'S NOT THE CHOICE
24	HERE. THIS IS A LOAN ON TERMS THAT ARE NOT POSITIVE
25	FOR CIRM OR THE TAXPAYERS OF CALIFORNIA.

48

1	DR. TROUNSON: I APPRECIATE THAT. IN
2	TERMS OF THE GRANTS, THERE'S A RETURN IF THEY'RE
3	VERY SUCCESSFUL AND THEY GET COMMERCIALIZED AND
4	THERE'S AN IP COMPONENT THAT WILL RETURN AGAIN IF
5	IT'S UTILIZED. ALL OF THOSE ARE PROBABILITIES THAT
6	ARE ATTACHED WHENEVER YOU INVEST IN A GRANT.
7	IN TERMS OF A LOAN, THE MONEY WILL COME
8	BACK BECAUSE IT'S A LOAN TO THE COMPANY, AND THAT
9	WILL BE REINVESTED FOR THE TAXPAYER, FOR THE
10	COMMUNITY AS IF IT HADN'T BEEN INVESTED IN THE FIRST
11	PLACE. AND SO ONE WOULD HOPE THE BENEFITS THAT ARE
12	ACCRUING FROM THOSE DEVELOPMENTS HAVE A BETTER
13	EFFECT ON THE BOTTOM LINE FOR HEALTHCARE BECAUSE
14	THAT IS THE LARGEST COMPONENT OF BENEFIT IN THE
15	LONGER TERM.
16	MR. TORRES: I THINK IT'S IN YOUR PACKET,
17	A ONE-PAGER WHICH WAS APPROVED BY THE BOARD
18	YESTERDAY, WHICH DR. TROUNSON IS REFERENCING, IN
19	RESPECT TO WHAT'S GOING TO BE RETURNED.
20	MEMBER KOVACH: WELL, THE PROOF WILL BE IN
21	HOW MANY LOANS ARE ACTUALLY DONE, RIGHT?
22	DR. TROUNSON: YES.
23	MEMBER KOVACH: BECAUSE YOU CAN'T FORCE
24	THE COMPANIES TO TAKE IT; BUT AT THE SAME TIME, YOU
25	PROBABLY DO YOU DISCUSS THE SUBJECT MATTER OF THE
	49
	· · · · · · · · · · · · · · · · · · ·

1 LOAN ITSELF? 2 DR. TROUNSON: YES. WE INVEST A LOT OF TIME THROUGH THE GENERAL COUNSEL IN THOSE 3 DISCUSSIONS AND NEGOTIATIONS EACH AND EVERY TIME. 4 IF THERE'S MORE THAN A \$3 MILLION GRANT, THEN THE 5 ONUS IS ON THE COMPANY TO TAKE THE LOAN RATHER THAN 6 7 THE GRANT. AND AT THIS STAGE, IF THEY'VE BEEN 8 AWARDED, THEY TAKE THE LOAN, BUT IT'S ONLY ONE THAT 9 HAS BEEN TAKEN. PROBABLY IN SOME CIRCUMSTANCES 10 COMPANIES HAVE AVOIDED MAKING AN APPLICATION BECAUSE OF THE CONCERNS ABOUT IN THE PAST THE CONDITION OF 11 12 THE LOAN. 13 MEMBER KOVACH: RIGHT. SO IT SEEMS LIKE IT'S A BALANCE. ON THE ONE HAND, YOU WANT TO PLACE 14 THESE LOANS. ON THE OTHER HAND, YOU HAVE TO DO IT 15 16 AT A RATE THAT PROVIDES CERTAINTY THAT A COMPANY 17 WILL ACTUALLY BE WILLING TO DO IT. DR. TROUNSON: YES. THAT'S EXACTLY RIGHT. 18 19 MEMBER LIPSON: NOW, DIDN'T YOU GET WARRANTS? YOU MENTIONED THE IDEA OF GETTING 20 21 WARRANTS ALSO. IN A WAY THAT'S ROYALTIES 22 INDI RECTLY. DR. TROUNSON: WITH WARRANTS, WE HAVE ONE 23 24 LOAN THAT INVOLVES WARRANTS. BUT WE HAD A VERY 25 STRONG PUSHBACK FROM INDUSTRY GENERALLY AGAINST USE 50

1	OF WARRANTS BECAUSE IT HAS A VERY DETRIMENTAL
2	EFFECT, ACCORDING TO THEIR FINANCIAL OFFICERS, ON
3	THEIR ACCOUNTS THAT IS CARRIED AS A DEBT. SO THEY
4	AVOID THAT, MOST COMPANIES. MOST OF THE COMPANIES
5	THAT WE TALKED TO WANT TO AVOID THAT AT ANY COST.
6	CHAIRMAN CHIANG: HOW WOULD THE TERMS THAT
7	CIRM SET YESTERDAY COMPARE TO THE PRIVATE SECTOR?
8	DR. TROUNSON: DO YOU WANT TO ANSWER THAT,
9	JAMES? YOU DID SOME OF THE PRESENTATION.
10	MR. HARRISON: JAMES HARRISON. FIRST
11	THING THAT YOU SHOULD UNDERSTAND IS THAT CIRM'S
12	TARGET FOR THESE LOANS ARE NOT NECESSARILY COMPANIES
13	THAT CAN GO OUT AND GET LOANS FROM ANY BANK. WHAT
14	CIRM IS TRYING TO ADDRESS IS WHAT'S KNOWN AS THE
15	VALLEY OF DEATH WHERE COMPANIES MAY HAVE A TERRIFIC
16	IDEA, BUT BECAUSE IT'S SO NEW AND NOVEL, BECAUSE OF
17	THE UNCERTAINTY ASSOCIATED WITH IT, THEY CAN'T GET
18	THE MONEY NECESSARY TO PUSH IT THROUGH PHASE I OR
19	PHASE II TO PROVE EFFICACY AND BRING IT TO THE
20	MARKET EVENTUALLY.
21	SO CIRM IS REALLY TARGETING A DIFFERENT
22	MARKET. IN TERMS OF TERMS OF THE LOANS THEMSELVES,
23	THE OPTION THAT THE BOARD ADOPTED YESTERDAY, WHICH
24	REQUIRES A RISK PREMIUM PAYBACK, WORKS AS FOLLOWS.
25	FOR WHAT'S KNOWN AS A PRODUCT-BACKED LOAN, A LOAN
	F1

51

1	WHERE REPAYMENT OF THE PRINCIPAL AND INTEREST IS
2	CONTINGENT UPON SUCCESS OF THE CIRM-FUNDED PROJECT,
3	THEY WOULD BE REQUIRED TO PAY UP TO 500 PERCENT OF
4	THE PRINCIPAL OF THE LOAN BACK TO CIRM IN ADDITION
5	TO THE PRINCIPAL AND INTEREST ITSELF.
6	THERE'S ANOTHER CATEGORY OF LOANS,
7	COMPANY-BACKED LOANS, WHERE THE COMPANY IS REQUIRED
8	TO REPAY THE LOAN REGARDLESS OF WHETHER THE PRODUCT
9	THAT CIRM HAS FUNDED IS SUCCESSFUL OR NOT.
10	DEPENDING UPON REVENUE THRESHOLDS THAT ARE MET FOR
11	THE PURPOSES OF THAT LOAN, THEY WOULD BE REQUIRED TO
12	REPAY A RISK PREMIUM UP TO 300 PERCENT OF THE AMOUNT
13	OF THE LOAN, AGAIN IN ADDITION TO PAYING THE
14	PRINCIPAL AND INTEREST OF THE LOAN.
15	THIS PROGRAM IS ACTUALLY VERY SIMILAR TO
16	ONE THAT THE JUVENILE DIABETES RESEARCH FOUNDATION
17	HAS INSTITUTED. AND IT'S WORKED VERY WELL. AS
18	SOMEONE SAID, DR. KOVACH, THE PROOF WILL BE IN
19	WHETHER WE'RE ACTUALLY ABLE TO IMPLEMENT THE PROGRAM
20	IN A WAY THAT WORKS BOTH FROM CIRM'S PERSPECTIVE AS
21	WELL AS THE COMPANY'S PERSPECTIVE SO THAT WE HAVE
22	MORE OF A VOLUME OF LOANS THAN WE HAVE CURRENTLY.
23	MEMBER LIPSON: HOW IS THE TAXPAYER PAID
24	BACK?
25	MR. HARRISON: WELL, THE TAXPAYER IS PAID
	50
	52

_	
1	BECAUSE THE MONEY GOES BACK TO CIRM FOR THE EXPRESS
2	PURPOSE OF USING FOR ADDITIONAL GRANTS AND LOANS TO
3	FURTHER THE MISSION OF THE AGENCY.
4	MEMBER LIPSON: BUT NO MONEY GOES BACK TO
5	THE BONDS?
6	MR. HARRISON: WITH RESPECT TO THE LOANS,
7	NO. WITH RESPECT TO GRANTS, CIRM HAS ADOPTED
8	INTELLECTUAL PROPERTY PROVISIONS AS SUPPLEMENTED BY
9	SB 1064, WHICH WAS ENACTED LAST YEAR, THAT
10	SPECIFICALLY REQUIRES REVENUE SHARING TO GO DIRECTLY
11	TO THE GENERAL FUND. LOANS UNDER THE LAW ITSELF,
12	THE RETURN IS TO CIRM TO PROVIDE ADDITIONAL GRANTS
13	AND LOANS.
14	MEMBER LIPSON: SO BASICALLY IT'S TO THE
15	ADVANTAGE OF CIRM AS AN INSTITUTION IN AND OF ITSELF
16	TO GET LOANS.
17	MR. HARRISON: WELL, I THINK CIRM
18	RECOGNIZES IT HAS AN OBLIGATION TO THE TAXPAYERS.
19	AND OBVIOUSLY THE FACTS SPEAK FOR THEMSELVES. TO
20	DATE CIRM HAS ISSUED ONLY ONE LOAN. THE REST HAVE
21	BEEN IN THE FORM OF GRANTS.
22	MEMBER KOVACH: I WOULD EMPHASIZE THE
23	BENEFIT OF THERAPIES. THEY DON'T CALL IT THE VALLEY
24	OF DEATH FOR NOTHING. AND WHEREAS GENERAL MAJOR
25	PHARMACEUTICAL COMPANIES WITH SMALL MOLECULES
	53

1	INNOVATE BY GOING FROM A FOUR-HOUR RELEASE TO AN
2	EIGHT-HOUR RELEASE AND 20 MORE YEARS OF PATENT,
3	WE'RE TALKING ABOUT THERAPIES THAT ARE IN THE
4	THAT IN MANY CASES HAVE FANTASTIC POTENTIAL, BUT
5	COMPANIES, IF THEY DON'T HAVE THE CERTAINTY, THEY
6	WILL NOT INVEST THE MONEY.
7	MR. HARRISON: THAT'S A VERY GOOD POINT.
8	I SHOULD ADD THAT WHEN THE INITIAL ECONOMIC
9	PROJECTIONS WERE DONE OF THIS PROGRAM, THE ESTIMATES
10	WERE THAT 90 PERCENT OF THE BENEFIT WOULD COME IN
11	THE FORM OF HEALTHCARE SAVINGS FROM THE EVENTUAL
12	THERAPIES THAT HOPEFULLY ARISE OUT OF THIS, NOT FROM
13	THE ROYALTIES THAT WOULD FLOW TO THE STATE. THE
14	FOCUS REALLY IS ON GETTING THE THERAPIES TO THE
15	MARKET AND TO PATIENTS AS QUICKLY AND AS EFFICIENTLY
16	AS POSSIBLE.
17	CHAIRMAN CHIANG: ANY OTHER QUESTIONS?
18	MR. TORRES: WITH YOUR INDULGENCE, TO MOVE
19	TO THE NEXT ITEM.
20	CHAIRMAN CHIANG: GOING TO THE NEXT ITEM.
21	YOU HAVE SOMETHING?
22	MR. TORRES: RELATED TO THE NEXT ITEM.
23	CHAIRMAN CHIANG: NEXT ITEM IS
24	PRESENTATION OF CIRM'S REPORT OF THE EXTERNAL
25	ADVI SORY COMMITTEE.
	F 4

1	MR. TORRES: BEFORE DR. TROUNSON PRESENTS
2	THAT, I WANTED TO EDUCATE THE MEMBERS OF THE
3	COMMITTEE THAT WE TOOK VERY SERIOUSLY THE TRANSCRIPT
4	FROM LAST YEAR'S MEETING, AND ESPECIALLY THE
5	CONCERNS OF THE CONTROLLER IN RESPECT TO OUR
6	INTERNAL OPERATIONS. AND WE HAVE ABIDED BY ALL THE
7	RECOMMENDATIONS WHERE WE COULD. AND THE REMAINDER
8	OF THE RECOMMENDATIONS THAT WE ABIDED BY WERE WITHIN
9	THE LEGISLATION KNOWN AS SB 1064 BY SENATOR ALQUIST.
10	WE'RE ALSO MOVING AHEAD, AND I'M WORKING
11	WITH MR. ROBSON ON MOVING AHEAD TO ESTABLISH THE
12	PERFORMANCE AUDIT PARAMETERS AS REQUESTED BY THE
13	LEGISLATION. SO THAT WILL BE REVIEWED BY 2010 AND
14	2011. WE'VE ALSO ADOPTED THE IP PROVISIONS, WHICH
15	YOUR COMMITTEE HAD CONCERNS ABOUT LAST YEAR AS WELL,
16	WHICH WERE ALSO PUT AS AN MANDATE WITHIN THE ALQUIST
17	LEGI SLATI ON.
18	WE'VE ALREADY TALKED ABOUT THE 50-PERSON
19	CAP. AND ALSO YOU ASKED TO PUBLISH THE TALLIES OF
20	ICOC VOTE TALLIES AND CONFLICTS OF INTEREST IN THE
21	MINUTES OF THE ICOC MEETINGS. YOU ALSO ASKED US AND
22	WE FINALLY DID BEGIN POSTING OUR FORM 700 ON OUR
23	WEBSITE AS WELL AS WE WILL BE POSTING ON A QUARTERLY
24	BASIS AND WORKING WITH YOUR OFFICE TO DETERMINE
25	EXACTLY SPECIFICALLY WHAT YOU WANTED US TO POST ON

55

-	
1	TRAVEL CLAIMS AND OTHER EXPENSES THAT OUR SENIOR
2	MANAGEMENT AND THE CHAIR AND VICE CHAIR AS WELL AS
3	OUR EMPLOYEES WILL BE SUBJECT TO DO.
4	DR. TROUNSON REPORTED THAT TO US, TO THE
5	BOARD, YESTERDAY ABOUT HOW WE SHOULD PROCEED. AND
6	WE ALL AGREE THAT THAT WAS A VERY APPROPRIATE WAY TO
7	GO.
8	THE OTHER ISSUE
9	CHAIRMAN CHIANG: CAN I PUT YOU ON THE
10	SPOT ON THAT? WE REQUESTED THAT LAST YEAR. IT JUST
11	CAME UP YESTERDAY?
12	MR. TORRES: YES. IT TAKES A WHILE TO
13	BUILD CONSENSUS ON A BOARD OF THIS NATURE
14	UNFORTUNATELY.
15	WE ALSO WANTED TO MAKE NOTE OF THE
16	CONCERNS THAT MS. LANSING, AS CHAIR OF OUR
17	GOVERNANCE COMMITTEE, EXPRESSED TO YOU, MR.
18	CONTROLLER, ABOUT TWO WEEKS AGO OUTLINING OUR
19	EFFORTS ON THE GOVERNANCE COMMITTEE TO ESTABLISH A
20	TRANSPARENT PROCESS IN THE SELECTION RATHER THE
21	NOMINATION AND ELECTION OF A NEW CHAIR TO REPLACE
22	MR. KLEIN, WHO HAS INDICATED HE WILL STEP DOWN
23	WITHIN SIX MONTHS. WE HAVE TAKEN THOSE STEPS
24	YESTERDAY MUCH MORE QUICKLY THAN WE HAVE TAKEN OTHER
25	STEPS, AS NOTED BY THE CONTROLLER.

56

1	AND WE ARE BASICALLY INCORPORATING THE
2	SUGGESTIONS OF DR. POMEROY, WHO'S ON OUR BOARD, TO
3	MAKE SURE THAT, NO. 1, WE PROVIDE A SELF-ASSESSMENT
4	OF OUR FUNCTION, OF OUR BOARD PERFORMANCE AND
5	FUNCTION; THAT WE, SECONDLY, PROVIDE INDIVIDUAL
6	BOARD MEMBERS TO EVALUATE THEMSELVES FOR THE
7	PURPOSES OF THE BOARD TO REVIEW; AND, THIRDLY, TO
8	DETERMINE BY SURVEY BY BOARD MEMBERSHIP AS TO WHAT
9	KIND OF CHAIR THEY REALLY WANT.
10	I THINK THAT DEBATE WAS STIRRED IN THE
11	LAST FEW WEEKS, AND YOU WERE VERY MUCH AWARE OF
12	THAT. SHOULD THE NEW CHAIR BE A SCIENTIST? SHOULD
13	THE NEW CHAIR BE A LAYPERSON? WHAT ARE THE
14	QUALITIES OTHER THAN ARE MANDATED BY THE
15	CONSTITUTION SHOULD WE LOOK AT IN TERMS OF A NEW
16	CHAIR? AND THAT WAS ALSO DISCUSSED. AND WE HOPE TO
17	COMPLETE THAT SURVEY WITHIN TWO WEEKS AND REPORT
18	THAT TO YOU, MR. CONTROLLER, BASED UPON THE
19	CONVERSATIONS, THE COMMITMENTS THAT I AND SHERRY
20	LANSING MADE TO YOU DIRECTLY IN RESPECT TO
21	IMPLEMENTING THOSE ELEMENTS.
22	I'D NOW LIKE TO ASK DR. TROUNSON TO
23	PRESENT A REPORT OF THE EXTERNAL ADVISORY PANEL,
24	WHICH YOU WERE VERY CONCERNED ABOUT AS WELL, TO LET
25	YOU KNOW WHO PARTICIPATED AND WHAT THEIR RESULTS
	57

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	AND, MORE IMPORTANTLY, WHAT DR. TROUNSON'S REACTION
2	WAS TO THAT ADVISORY PANEL.
3	CHAIRMAN CHIANG: ART, I JUST WANT TO GET
4	A CLARIFICATION. THE SURVEY, THE MEMBERS OF THE
5	GOVERNING BOARD HAVE TO RETURN THE SURVEY WITHIN TWO
6	WEEKS, AND THEN WHEN WILL BE GET THE REPORT?
7	MR. TORRES: I WOULD PREFER TO SHARE THAT
8	INFORMATION WITH YOU AS SOON AS WE RECEIVE IT. IT
9	WILL BE ANONYMOUSLY DONE BY THE BOARD MEMBERS. I
10	DON'T THINK THERE'S ANY PROBLEM IN SHARING THAT WITH
11	YOU, AND THAT WOULD BE MY COMMITMENT TO YOU.
12	MEMBER LOTT: MR. CHAIRMAN, WITH THE
13	TRANSITION FROM THE EXISTING CHAIR TO A NEW CHAIR,
14	THERE SEEMS TO BE AN OPPORTUNITY, I THINK, HERE TO
15	CLARIFY THE ROLE BETWEEN THE PRESIDENT AND THE
16	CHAIRPERSON OF CIRM. BECAUSE IT'S INTERESTING, TO
17	PUT IT MILDLY. AND WHAT YOU ALL ARE REVIEWING AND
18	PREPARING TO DO FOR THIS TRANSITION, IS THAT A
19	CONSI DERATI ON?
20	MR. TORRES: YES, ABSOLUTELY. IN FACT, IT
21	WAS DR. TROUNSON, WHO AS PART OF HIS EVALUATION AS
22	PRESIDENT OF OUR INSTITUTION, BROUGHT FORWARD A
23	REORGANIZATION PLAN THAT ADDRESSES THAT. THANK GOD
24	HE AND MR. KLEIN HAVE HAD AN INCREDIBLE
25	RELATIONSHIP. YES, THEY ARGUED OVER POINTS HERE AND

58

1	THERE, BUT NEVER PUBLICLY, BUT RESOLVED THEM. I
2	THINK THAT WAS TO THE BOARD'S TREMENDOUS EMBRACE
3	YESTERDAY.
4	SO PART OF THAT REORGANIZATION THAT DR.
5	TROUNSON PRESENTED TO OUR BOARD AND PRESENTED TO
6	STAFF THIS MORNING IS SPEAKING ABOUT THAT
7	INTERACTION. A LOT OF IT IS ON COMMUNICATIONS
8	ISSUES, AS DR. TROUNSON ARTICULATED, AS WELL AS
9	MAKING SURE THAT THERE'S A CLEAR DIVISION OF LABOR
10	AND JURISDICTION SO THAT WHEN A NEW CHAIR COMES IN,
11	AT THAT APPROPRIATE TIME THE GROUND RULES ARE PRETTY
12	MUCH LAID AS TO HOW THOSE TWO INDIVIDUALS ARE GOING
13	TO BE INTERACTING AND THE JURISDICTION OF THEIR
14	INTERACTIONS. DR. TROUNSON.
15	DR. TROUNSON: THANK YOU VERY MUCH. I
16	GUESS YOU COULDN'T IMAGINE ME EVER ARGUING WITH BOB
17	KLEIN, WOULD YOU? THE WHOLE IDEA IS NEVER TO DO IN
18	PUBLIC IF YOU HAVE A DISAGREEMENT, TO RESOLVE IT. I
19	THINK YOU MADE GOOD POINTS, AND IN MANY RESPECTS IT
20	DEPENDS ON WHO GETS APPOINTED TO BE THE NEW CHAIR,
21	OF COURSE, AND WHAT BACKGROUND CAPACITY THEY HAVE
22	AND HOW THEY WANT TO ACT AS CHAIR. IT MAY WELL BE
23	DIFFERENT THAN MR. KLEIN.
24	MEMBER LOTT: I'M GOING A LITTLE BIT
25	FURTHER THAN THAT. WHO GETS IT, AND THAT HE OR SHE
	50
	59

1	MAY MAKE IT DIFFERENT, WILL THERE BE SOME DIVISION
2	OF LABOR THAT'S PRESCRIBED? WHOEVER THE HECK IT IS
3	THAT COMES ON BOARD UNDERSTANDS THAT HE OR SHE HAS
4	CERTAIN POWERS.
5	DR. TROUNSON: YES. I THINK THERE IS
6	PRETTY CLEAR BOUNDARIES AT THE PRESENT STAGE.
7	MEMBER LOTT: NO, THERE ISN'T. I KNOW
8	THERE AREN'T. I'M SORRY. RIGHT NOW, RIGHT NOW IT'S
9	NOT CLEAR AT ALL. AND THE CHAIRMAN, GOD BLESS HIM,
10	IS DOING MORE OF THE HANDS-ON RUNNING OF THE
11	ORGANIZATION THAN CHAIRMEN OF MOST ORGANIZATIONS DO.
12	WE JUST NEED TO BE REAL CLEAR ABOUT THAT.
13	DR. TROUNSON: I APPRECIATE YOUR CONCERN.
14	I ACTUALLY WORK IN THAT OFFICE IN THE INTERACTION
15	WITH HIM, SO I ABSOLUTELY KNOW HOW MUCH HE IMPACTS
16	ON THE ORGANIZATION. SO YOU' RE RIGHT. COMPARED TO
17	WHAT YOU'D EXPECT OF A CONVENTIONAL BOARD, IT'S VERY
18	DIFFERENT. IT'S MORE LIKE AT TIMES AN EXECUTIVE
19	CHAIR. BUT I TOOK THE JOB TO WORK TOGETHER WITH
20	MR. KLEIN AS PRESIDENT AND I HAVE. AND I WOULD HOPE
21	THAT THE FURTHER CLARITY THAT YOU ARE SEEKING WOULD
22	ALSO HAPPEN, BUT WE ARE VERY CLEAR AT THE MOMENT
23	WHERE THE DIVISION OCCURS. BETWEEN HE AND I, WE ARE
24	VERY CLEAR ABOUT THAT. WE DON'T ALWAYS AGREE, BUT
25	WE'RE CLEAR ABOUT THAT.

60

1	IF I COULD GO TO THE NEXT SLIDE, IF I MAY.
2	THE PURPOSE OF THIS REVIEW WAS SET UP REALLY IN THE
3	2006 STRATEGIC PLAN, AND IT WAS RECOMMENDED IN THAT
4	PLAN THAT A FORMAL ASSESSMENT BY AN OUTSIDE PANEL
5	WAS MADE AT YEAR THREE AND YEAR SEVEN. LAST YEAR
6	WAS YEAR THREE OF OPERATIONS.
7	AND SO THE GOALS OF THE EVALUATION WERE TO
8	LOOK AT CIRM'S PROGRAMS, PROGRESS IN ITS PROGRAMS
9	AGAINST ITS GOALS, ASSESS THE EFFECTIVENESS OF
10	MOVING CIRM TOWARDS MEETING THOSE GOALS, AND
11	ACCOMPLISHING THE OVERALL MISSION, AND RECOMMENDING
12	CHANGES IN THE FUNDING PRIORITIES TO ENSURE THAT
13	CIRM IS REALLY SUPPORTING THE MOST PROMISING
14	ADVANCES IN THE WHOLE FIELD OF REGENERATIVE
15	MEDICINE, AND OTHER FEEDBACK AS WAS NECESSARY. SO
16	THAT WAS THE PURPOSE OF THE REVIEW.
17	THESE ARE THE PANELISTS THAT WERE ASKED TO
18	BE THE REVIEW PANEL. DR. ALAN BERNSTEIN, WHO WAS
19	THE CHAIR, IS THE FOUNDING EXECUTIVE DIRECTOR OF THE
20	CANADIAN INSTITUTES OF HEALTH RESEARCH, RETIRED FROM
21	THAT, BUT HE IS THE HEAD OF CHAIRMAN OF THE
22	GLOBAL HIV VACCINE ENTERPRISE, AND HE'S SITED IN NEW
23	YORK.
24	DR. GEORGE DALEY IS ONE OF THE MOST
25	PROMINENT MEDICAL RESEARCHERS IN STEM CELLS AT
	61

1	HARVARD. HE WORKS IN STEM CELLS. HE WOULD BE
2	RANKED AMONGST THE TOP THREE OR FOUR SCIENTISTS IN
3	THE WORLD.
4	PROFESSOR SIR MARTIN EVANS IS A NOBEL
5	LAUREATE, WAS AWARDED THE NOBEL LAUREATE IN STEM
6	CELLS. HE HOLDS A PROFESSORIAL POSITION AT CARDIFF
7	UNIVERSITY IN WALES.
8	DR. IGOR GONDA, CEO ARADIGM CORPORATION.
9	PROFESSOR JUDY ILLES, NEUROLOGY AND NEUROETHICS AT
10	THE UNIVERSITY OF BRITISH COLUMBIA. DR. RICHARD
11	INSEL IS THE CHIEF SCIENTIFIC OFFICER AND EXECUTIVE
12	VICE PRESIDENT OF RESEARCH AT THE JUNIOR DIABETES
13	RESEARCH FOUNDATION. DR. RICK KLAUSNER FROM THE
14	COLUMN GROUP AND IS THE EX-EXECUTIVE DIRECTOR OF THE
15	GATES FOUNDATION FOR GLOBAL HEALTH, AND WAS ALSO THE
16	DIRECTOR OF THE NATIONAL CANCER INSTITUTE AT NIH.
17	AND FINALLY, DR. NANCY WEXLER IS PRESIDENT OF THE
18	HEREDITARY DISEASE FOUNDATION AND PROFESSOR OF
19	NEUROPSYCHOLOGY AT COLUMBIA UNIVERSITY.
20	SO THE PROCESS THAT WE DEVELOPED WAS THAT
21	IN OCTOBER WE HAD THE EXTERNAL REVIEW PANEL MEET
22	WITH US IN SAN FRANCISCO OVER THREE DAYS. AND THEY
23	ALSO MET WITH THE COMMUNITY, THEY MET WITH THE
24	SCIENTISTS OF CALIFORNIA, THEY MET WITH PATIENT
25	ADVOCATES OF CALIFORNIA, THEY MET WITH THE BUSINESS
	40

62

1	INDUSTRY OF CALIFORNIA. AND THEY ALSO HAD SEVERAL
2	MEETINGS IN PUBLIC WITH PEOPLE WHO HAD INTEREST FROM
3	THE PUBLIC.
4	IN DECEMBER THE 8TH THE REVIEW WAS
5	PRESENTED TO THE ICOC IN OPEN DISCUSSION BY PUBLIC
6	WITH THE BOARD. ON DECEMBER 9TH MANAGEMENT BEGAN
7	MEETINGS TO DISCUSS THE REPORT AND RESPONSE.
8	FEBRUARY 14TH MANAGEMENT WILL BE PROVIDING DRAFT
9	OPERATIONAL DOCUMENTS TO THE CHAIR AND VICE CHAIRS
10	FOR COMMENTS ON THE REVIEW. AND IN MARCH WE'LL MAKE
11	THE FINAL REVISIONS AFTER GETTING OUR FEEDBACK, AND
12	WE'LL POST THE DOCUMENT ON OUR WEBSITE, AND MARCH
13	10TH PRESENT TO THE ICOC FOR DISCUSSION AND ACTION.
14	AND THEN BY MARCH 20TH FINALIZE AND POST DOCUMENTS
15	AND BEGIN IMPLEMENTATION. SO THAT'S THE AGREED
16	PROCESS TO THE REVIEW, WHICH IS CRITICAL.
17	SO LOOKING AT THE PARTICULAR ISSUES, I
18	WANTED TO GO JUST THROUGH THOSE PARTICULAR ISSUES.
19	AND THIS IS MY RESPONSE, AND IT WAS REALLY MY
20	RESPONSE TO THE BOARD RATHER THAN THE WHOLE OF
21	MANAGEMENT'S RESPONSE BECAUSE AT THAT STAGE I HADN'T
22	HAD THE OPPORTUNITY TO GET ALL THE RESPONSE BECAUSE
23	WE'D ONLY JUST RECEIVED THE DOCUMENT.
24	NO. 1 WAS TO MAINTAIN FOCUS ON MEANINGFUL
25	SCIENTIFIC EXCELLENCE. AND THAT REALLY, THE RED
	63

1	MEANS, AS WE INTERPRET IT, ENSURE THE SCIENTIFIC
2	INTEGRITY OF THE GRANTS REVIEW IS MAINTAINED AND
3	IMPROVED. AND SO WE WOULD BE ADDRESSING THAT IN
4	THAT REGARD.
5	SECONDLY, TO SUSTAIN FUNDAMENTAL
6	DISCOVERY. THAT'S IN THE BASIC RESEARCH. THAT
7	MEANS TO MAINTAIN STRONG BASIC SCIENCE DISCOVERY AND
8	TRAINING PROGRAMS, WHICH WE WILL CONTINUE.
9	THIRD, HAVING A PATH FROM FUNDAMENTAL TO
10	TRANSCRIPTIONAL RESEARCH. THAT IS, TAKE TO THE
11	CLINIC TRANSLATIONAL MEDICINE, PRODUCT DEVELOPMENT,
12	AND HEALTHCARE DELIVERY, WHICH IS THE MOST
13	MEANINGFUL PART, TO THE CALIFORNIA COMMUNITY,
14	GENERAL COMMUNITY.
15	SO REALLY THIS IS TO DEVELOP A MORE
16	AGGRESSIVE, PROACTIVE APPROACH TO IDENTIFY
17	INNOVATION ACROSS THE WHOLE THERAPEUTIC LANDSCAPE
18	AND FULLY ENGAGE INDUSTRY IN THE DELIVERY OF THE
19	THERAPEUTICS. THAT WAS REALLY WHAT THEY WERE
20	SEEKING. SO WE ARE GATHERING INTELLIGENCE ON THE
21	RAPIDLY MOVING RESEARCH AND TRANSLATION THROUGH KEY
22	CONFERENCES, SCIENTISTS REVIEWING HOT AREAS OF
23	BREAKING SCIENCE, SCIENCE AND INDUSTRY ADVISORY
24	GROUPS, AND COLLABORATING FUNDING PARTNERS THAT WE
25	HAVE ACROSS THE U.S. IN DIFFERENT STATES AND

64

1	INTERNATIONALLY IN DIFFERENT COUNTRIES. AND WE ARE
2	IDENTIFYING CALIFORNIA PARTNERS FOR THESE NEW
3	DEVELOPERS AND ARRANGING APPROPRIATE LINKAGE.
4	WE WANT TO ENABLE APPROPRIATE ENTRY OF
5	THESE NEW ADVANCES INTO THE PROCESS. SO THEY WANTED
6	TO BE MORE PROACTIVE, GO OUT AND GET THE BEST, BRING
7	IT TO CALIFORNIA, AND MAKE IT HAPPEN. THEY'VE GIVEN
8	US A VERY STRONG ENDORSEMENT TO WHAT WE'VE BEEN
9	DOING, BUT THEY SAID IN PHASE II REALLY GET OUT OF
10	THE BLOCKS AND REALLY PERFORM WAY ABOVE ALL
11	EXPECTATI ONS.
12	A PORTFOLIO PRIORITIZATION PROCESS, THEY
13	DIRECTED US TO LOOK AT OUR PORTFOLIO BECAUSE THEY
14	FELT THAT IT WAS EXTREMELY BROAD AND WIDE ACROSS THE
15	SPACE. AND IN THEIR VIEW, IT WAS UNLIKELY TO
16	PRODUCE THE SAME OUTCOMES THAT SOME MORE FOCUS WOULD
17	ACHIEVE. SO EMBEDDED IN THAT IS TO CREATE AN
18	ADVISORY GROUP, INCLUDING OUTSIDE INTERDISCIPLINARY
19	EXPERTS, TO CONDUCT A CRITICAL ASSESSMENT OF OUR
20	CURRENT PORTFOLIO WITH OBJECTIVE BENCHMARKS TO
21	IDENTIFY PROGRAMS THAT DESERVE SOME SUPPORT AND MOVE
22	FORWARD THOSE THAT SHOULD NOT.
23	SO YOU WILL RECOGNIZE ACROSS KIND OF THE
24	SPACE WE'VE GOT AND A VARIETY OF ADVOCATES ON OUR
25	BOARD AND ADVOCATES INPUTTING INTO US THAT THE
	65

1	PRESSURE IS TO KEEP US SO OPEN AND SO BROAD, AND
2	THEY'RE WANTING US TO NARROW DOWN AND GET THE BEST
3	DEVELOPMENTS AND TAKE THEM FORWARD BECAUSE THERE'S A
4	LIMIT. \$3 BILLION IS A LOT OF MONEY, NO DOUBT; BUT
5	IF YOU ARE GOING TO AFFECT A VERY LARGE SPACE, YOU
6	WILL POSSIBLY HAVE A SMALL IMPACT; BUT IF YOU CAN
7	GET IT NARROWED DOWN, YOU'RE LIKELY TO HAVE A BIGGER
8	IMPACT. THAT WAS THEIR FEELINGS.
9	FOCUS ON A NUMBER OF PROJECTS TO THOSE
10	THAT BELIEVE MAY HAVE THE GREATEST CHANCE OF
11	DEVELOPMENT AND CLINICAL SUCCESS GIVEN A REASONABLE
12	TIMELINE AND BUDGET. AND SO WE'VE GOT TO CONSIDER
13	HOW TO SUPPORT CRITICAL NEEDS IN TRANSLATION THAT
14	ENCOMPASS A WIDER SPECTRUM THAN A SINGLE DISEASE.
15	WHAT I MEAN BY THAT IS IN THE NEURODEGENERATIVE
16	DISEASES, FOR EXAMPLE, AND JIM WILL UNDERSTAND THIS
17	PERFECTLY, THE NEURODEGENERATIVE DISEASES LIKE
18	PARKINSON'S, ALZHEIMER'S, HUNTINGTON'S DISEASE,
19	MULTIPLE SCLEROSIS, THEY OFTEN HAVE A COMMON STOCK,
20	A COMMON ELEMENT. YOU COULD TAKE INFLAMMATION IN
21	THOSE DISEASES. INFLAMMATION WILL DRIVE THAT AS
22	PHENOTYPES, THE DISEASE CONDITION STRONGLY. IF YOU
23	CAN CONTROL THE INFLAMMATORY COMPONENT, YOU WOULD
24	MAYBE PUT OFF THE PHENOTYPE, THE BAD DISEASE,
25	OCCURRING FOR SOME TIME. IT'D STILL THERE, BUT YOU

66

1	WOULD PUT OFF THE SEVERITY OF THE CONDITION AND
2	MAYBE THE TIME FRAME.
3	SO IF YOU WORK ON A SINGLE STOCK PROCESS,
4	YOU COULD HAVE A PRETTY BIG IMPACT; WHEREAS, IF
5	YOU'RE WORKING ON EVERY INDIVIDUAL ONE AND BROADLY
6	ACROSS THE SPECTRUM, YOU MAY HAVE LESS IMPACT. SO
7	THERE'S JUST AN EXAMPLE OF WHAT WE MIGHT BE ABLE TO
8	ACHIEVE BY SORT OF NARROWING OUR FOCUS ON ONE
9	COMPONENT PART. I'M NOT SUGGESTING THAT THAT'S WHAT
10	WE DO, BUT WHAT WE NEED TO DO IS THINK ABOUT HOW TO
11	MAKE IT MORE EFFECTIVE.
12	SO THEY WANT AN OPEN INNOVATION, POROUS
13	PIPELINE. THE PIPELINE I'M TALKING ABOUT IS BASIC
14	RESEARCH THROUGH TO THE CLINIC. DISCOVERY AND THEN
15	YOU'VE GOT TO TURN IT INTO TRANSLATION, MAKE IT WORK
16	SO THAT IT CAN BECOME A TREATMENT FOR PATIENTS, AND
17	YOU' VE GOT TO ADDRESS THE ISSUES THAT THE REGULATOR
18	WANTS IN TRANSLATION IN TERMS OF PRECLINICAL WORK
19	AND THEN CLINICAL STUDIES. SO THAT'S THE PIPELINE
20	I'M TALKING ABOUT.
21	THEY WANT IT TO BE MUCH MORE OPEN AND
22	POROUS, ALLOWING ENTRY INTO THE PIPELINE IN A MUCH
23	MORE POROUS AND EFFECTIVE WAY AND ALLOW INDUSTRY
24	PARTICULARLY TO COME INTO THAT PIPELINE IN A MORE
25	FACILITATED MANNER.

67

1	SO CLINICAL PROJECTS COME FROM INSIDE OR
2	OUTSIDE CIRM-FUNDED RESEARCH, INCLUDING OUT OF
3	INDUSTRY OR EVEN OUTSIDE CALIFORNIA. THEY WANTED US
4	TO BROADEN THE PROSPECTS WHILE BRINGING A FOCAL
5	POINT TO CALIFORNIA, BRINGING IN THE BEST WORK, AND
6	ALLOW IT TO ENTER THAT PIPELINE. SO TO BE MORE
7	FLEXIBLE IN OUR FUNDING PROCESSES WITH LESS
8	ADMINISTRATIVE DOCUMENTATION, ROLLING FUNDING CYCLES
9	THAT COULD ALLOW FOR INNOVATIVE PROJECTS TO BE
10	CAPTURED, PARTICULARLY FROM INDUSTRY THAT MAY BE
11	OUTSIDE THE ESTABLISHED CYCLES BECAUSE A BUSINESS
12	REQUIRES MONEY AT A CERTAIN POINT OF TIME AND CAN'T
13	WAIT FOR A YEAR OR TWO YEARS TO GET THEIR FUNDING.
14	THE COMPANY WILL HAVE GONE BUST ESSENTIALLY. SO
15	THERE HAS TO BE SOME CONSIDERATION FOR THEIR
16	PARTICULAR NEEDS.
17	AND THE PROJECTS COULD ENTER THE CIRM
18	PIPELINE AT ANY STAGE OF PRECLINICAL AND CLINICAL
19	DEVELOPMENT, AND WE'VE BEEN ENABLING THAT TO HAPPEN
20	NOW.
21	SO THIS IS THE PIPELINE I'M TALKING ABOUT:
22	BASIC RESEARCH THROUGH TO THE CLINICAL TRIALS, WHICH
23	ARE OUT IN THE ORANGE ON THE OTHER SIDE. SO OFTEN
24	CIRM IS IN THE PROCESS OF RUNNING THE PROJECTS
25	THROUGH THE CENTRAL PIPELINE, BUT ALSO BRINGING IN
	68

68

1	PROJECTS FROM CALIFORNIA INTO EACH PART OF THAT
2	PIPELINE AT DIFFERENT SPOTS, BUT ALSO SOME EXTERNAL
3	AND INTERNATIONAL ENTRY POINTS INTO THAT. THIS THE
4	REVIEW COMMITTEE FELT THAT WE SHOULD HAVE A VERY
5	POROUS PIPELINE, IN THEIR VIEW, TO ENABLE THESE
6	THINGS TO REALLY, REALLY HAPPEN IN A VERY EFFECTIVE
7	WAY.
8	THEY WANTED US TO LOOK AT THE SOCIAL,
9	ETHICAL, AND HEALTHCARE DELIVERY AND REGULATORY
10	ISSUES, IDENTIFY AND STIMULATE RESEARCH IN CRITICAL
11	ETHICAL, ECONOMIC, MANUFACTURING, HEALTH DELIVERY,
12	AND SOCIAL ISSUES NEEDED FOR TRANSLATION INTO POLICY
13	AND PRACTICE, TO ESTABLISH AN ADVISORY GROUP TO
14	IDENTIFY THE CRITICAL ISSUES AND THE PRIMARY
15	ACTIVITIES NEEDED TO RESOLVE THESE, AND TAKE A
16	LEADERSHIP ROLE IN DEVELOPING STANDARDS FOR
17	MANUFACTURING, CELL INTEGRITY FOR RESEARCH AND
18	CLINICAL USE, POSSIBLY PROVIDE THERAPEUTIC DELIVERY
19	THROUGH CIRM-SPONSORED STEM CELL UNITS.
20	FOR EXAMPLE, I HAVE A VIEW THAT THE NORMAL
21	DRUG DELIVERY MODEL DOESN'T WORK PERFECTLY FOR WHAT
22	WE WANT TO DO WITH CELL THERAPIES. CELL THERAPY
23	ISN'T REALLY A DRUG. GIVE A DRUG TO A PATIENT, THE
24	DRUG DECAYS AWAY. GIVE A CELL TO A PATIENT, AND IT
25	INTEGRATES. THE CELL WILL BE THERE FOR THEIR

69

1	LIFETIME, REGENERATIVE. YOU HAVE TO LOOK AT THAT
2	QUITE DIFFERENTLY. AND IF YOU ARE GIVING PATIENTS
3	CELLS, I THINK YOU NEED TO THINK MORE ABOUT THE BONE
4	MARROW TRANSPLANTATION MODEL PERHAPS, A CLINIC UNIT
5	MODEL, CANCER CENTER MODEL, EVEN THE ONE THAT I KNOW
6	BEST, THE IVF MODEL WHERE YOU HAVE CLINICIANS AND
7	YOU HAVE CELL BIOLOGISTS AND MOLECULAR BIOLOGISTS
8	AND NURSING STAFF AND COUNSELORS ALL WORKING IN ONE
9	PLACE.
10	THAT'S WHAT I CALL AN ALPHA CLINIC,
11	SOMEWHERE THEY COULD DEVELOP THESE STEM CELL
12	THERAPIES, PROVIDE THEM FOR THE PATIENTS BECAUSE
13	THERE'S A LARGE NUMBER OF PATIENTS IN CALIFORNIA
14	GOING OUTSIDE TO GET TREATMENTS WHICH ARE NOT GOOD,
15	WHICH ARE NOT PROVEN, WHICH ARE NOT GOOD FOR THEIR
16	HEALTH, WHICH ARE DANGEROUS IN SOME INSTANCES. AND,
17	OF COURSE, YOU CAN UNDERSTAND WHY THEY DO IT.
18	BECAUSE THERE'S BETTER OPTIONS FOR THEM. WE SHOULD
19	BE ABLE TO NOW BRING THEM INTO STEM CELL CLINICS,
20	ALPHA CLINICS, WE SET UP THROUGH CALIFORNIA. I'M
21	HOPING THAT WE CAN DO THAT AND PROVIDE A PROPER
22	SERVICE BECAUSE THERE'S ENOUGH NOW ADULT STEM CELL
23	THERAPIES AVAILABLE, AND I THINK IF WE COULD GO TO
24	THE FDA SAYING THAT WE HAVE MAJOR CLINICAL SCIENCE,
25	THEY WOULD FEEL MUCH MORE COMFORTABLE ABOUT THE

70

MANAGEMENT AND THE CARE OF THE PATIENT IN THAT
ENVIRONMENT THAN IN THE SO-CALLED DRUG ENVIRONMENT
WHERE A DRUG IS GIVEN REALLY OUT OF THE PHARMACY AND
YOU MAY OR MAY NOT SEE THE PATIENT THEREAFTER.
SO THE WHOLE COST OF DELIVERING THESE
THERAPIES MIGHT BE REMODELED IN A WAY WHICH WOULD BE
MORE EFFECTIVE. SO I WANT TO LOOK AT THAT. AND
I'VE GOT A LOT OF SUPPORT INTERNALLY IN CALIFORNIA
TO DO THAT. AND THE REVIEW COMMITTEE FELT THAT THIS
WAS A VERY GOOD OPPORTUNITY TO LOOK AT, TO LOOK AT
IT, PROPERLY ANALYZE IT, LOOK AT IT IN DETAIL, AND
SEE IF IT WAS REALLY VIABLE.
SO DIVERSITY IN CIRM ACTIVITIES NEED TO BE
CONTINUOUSLY EXAMINED. STRATEGIES ADDRESSING
ECONOMIC BARRIERS THAT ARE IN EARLY DEVELOPMENT
SHOULD BE ACTIVELY PURSUED. I HAVE A VERY STRONG
VIEW MYSELF IN THAT TO ENSURE THAT WHEN WE DEVELOP
THESE THERAPIES, THAT WE NEED TO ABSOLUTELY MAKE
THEM AVAILABLE TO ALL THE PEOPLE OF CALIFORNIA. BUT
IN MY VIEW, IF WE DEVELOP A CURE FOR HIV, I'D LIKE
TO SEE IT GO ON TO END UP AS A THERAPY THAT CAN BE
DELIVERED TO THE WORLD IN TERMS OF A VACCINE. SO I
DON'T WANT TO STOP AT A CURE IN CALIFORNIA. I WANT
TO MAKE SURE IT ROLLS ONWARD TO THE WHOLE WORLD.
INDUSTRY ENGAGEMENT, WHICH IS WHERE THEY
71

71

1	FELT OUR MAJOR WHICH WAS OUR POOREST PERFORMANCE,
2	I THINK, IN THEIR ASSESSMENT. THEY WANTED US TO
3	HAVE A MORE SIGNIFICANT ENGAGEMENT WITH THE
4	BIOPHARMACEUTICAL INDUSTRY, MORE ACCOMMODATING TO
5	THEIR TIMELINES AND FINANCIAL RESTRAINTS AND TO
6	ESTABLISH THE SCOPE AND INTEREST OF ALL SECTORS IN
7	THE BIOPHARMA INDUSTRY IN PROVIDING SERVICES,
8	PARTNERING WITH CIRM AND ACADEMIA, DEVELOPING MAJOR
9	CRITICAL CAPACITY IN CELL MANUFACTURING.
10	YOU MIGHT BE INTERESTED THAT SOME OF THE
11	MAJOR COMPANIES IN CELL MANUFACTURING ARE NOW
12	LOOKING AT ENTERING INTO CALIFORNIA. THAT WOULD BE
13	A VERY BIG BONUS FOR CALIFORNIA TO HAVE THEM COME
14	I N.
15	MEMBER LOTT: MAY I STOP YOU THERE? HOW
16	WOULD YOU MANAGE THE POTENTIAL CONFLICT ISSUE?
17	DR. TROUNSON: WITH THE INDUSTRY?
18	MEMBER LOTT: YEAH. HOW WOULD YOU MANAGE
19	THAT?
20	DR. TROUNSON: THE CONFLICT IS FOR THE
21	SHAREHOLDER INFLUENCES. I'M UNDERSTANDING YOUR
22	MEANING, THERE WOULD BE SHAREHOLDER INTEREST IN THE
23	INDUSTRY; WHEREAS, WE'RE TRYING TO PROVIDE THE
24	INDUSTRY BROADLY FOR ALL CALIFORNIANS. I THINK WHAT
25	HAS HAPPENED IS THESE TWO THINGS HAVE TO COME TO AN
	70

72

1	INTERSECTION. THE BIOPHARMACEUTICAL INDUSTRY HAS
2	GOT A BIG PROBLEM. THE COST OF DELIVERING NEW DRUGS
3	IS NOW PEOPLE SAY IT'S A BILLION DOLLARS. THAT'S
4	NOT TRUE. IT'S CLOSER TO \$4 BILLION A DRUG. NOW
5	THAT'S JUST NOT SUSTAINABLE. IT CANNOT BE. SO
6	THEY'VE GOT TO ACTUALLY REINVENT THEMSELVES IN SOME
7	WAY, OR THE COMPANIES HAVE GOT TO REINVENT
8	THEMSELVES AND COME BACK AND ADOPT A MORE COMMUNITY
9	ORIENTED VIEW FOR THEIR SURVIVAL.
10	MEMBER LOTT: I UNDERSTAND IT. I
11	UNDERSTAND THAT THAT'S THEIR CHALLENGE, BUT YOU ARE
12	GOING TO BRING THEM INTO THE FOLD, WHICH I DON'T
13	I'M NOT COMMENTING ON IT AS BEING BAD. BUT BECAUSE
14	OF THE WAY THIS WHOLE INDUSTRY AND ALL OF WHAT WE DO
15	RELATE TO ONE ANOTHER, THERE'S A LOT OF CROSS
16	POLLENIZATION OF INTEREST. YOU HAVE PEOPLE INVOLVED
17	WITH SOME OF THESE ENTITIES WHO WILL BE INVOLVED
18	WITH UNIVERSITIES WHOM WE DEAL WITH AND GRANTS THAT
19	WE MAKE. HOW DO YOU MAKE CERTAIN THAT WE'RE NOT
20	CREATING A PROBLEM FOR OURSELVES BY BRINGING THESE
21	PEOPLE CLOSER TO US WHO MIGHT HAVE INTEREST IN OTHER
22	AREAS THAT WE DO BUSINESS WITH?
23	DR. TROUNSON: I THINK IN THE FIRST PLACE
24	WE'RE CHARGED WITH INTERSECTING WITH THE BIOTECH
25	INDUSTRY. THAT WAS WRITTEN INTO PROPOSITION 71. SO
	73

1	IN THE SENSE THAT WE NEED TO CONNECT WITH THE
2	SMALLER BIOTECH COMPANIES OR MEDIUM SIZED BIOTECH
3	COMPANIES, THAT'S REQUIRED. AND THAT IS PART OF
4	STIMULATING WHAT WOULD HAPPEN IN CALIFORNIA. SO WE
5	HAVE TO NEGOTIATE, WE HAVE TO BRING FORWARD
6	AGREEMENTS THAT RESPECT THE NEEDS FOR THE CALIFORNIA
7	COMMUNI TY.
8	MEMBER LOTT: YOU'RE NOT ANSWERING MY
9	QUESTION. YOU'RE NOT ANSWERING MY QUESTION. I
10	UNDERSTAND THAT WE HAVE TO DO IT AND WE WANT TO DO
11	MORE OF IT AND DO IT BETTER. I'M ASKING THE
12	QUESTION THOUGH FOR HOW WE MANAGE POTENTIAL
13	CONFLI CTS.
14	DR. TROUNSON: THE CONFLICTS, I THINK
15	WHAT I'M TRYING TO GET THROUGH IS TO THE CONFLICT, I
16	GUESS, IS THE CONFLICT OF THE COMPANY WANTING TO
17	MAKE MONEY AND THE COMMUNITY NEEDING TO HAVE
18	TREATMENTS MADE AVAILABLE TO THEM AT A REASONABLE
19	COST. AND THAT IS THE CONFLICT THAT I'M TRYING TO
20	ADDRESS, I THINK. IF THERE'S SOME OTHER FORM OF
21	CONFLICT THAT IS PRIMARY
22	MEMBER LOTT: MAYBE I'M JUST NOT GETTING
23	IT. IT COULD BE MY PROBLEM.
24	DR. TROUNSON: WELL, MAYBE I'M NOT
25	EXPLAINING IT WELL ENOUGH, AND I APOLOGIZE FOR THAT.
	74

1	BUT WE'RE ACTUALLY SEEING A CONVERGENCE OF INTEREST.
2	SO THE DISCUSSION THAT WE'RE HAVING WITH THE WHOLE
3	SECTOR IS LET'S TRY AND DO THESE THINGS TOGETHER TO
4	MAKE IT MORE EFFECTIVE. THAT MEANS THAT IT'S
5	MADE THESE TREATMENTS ARE MADE AVAILABLE TO THE
6	PATIENTS AT A REASONABLE COST AND A COST TO THE
7	COMMUNITY THAT'S BENEFICIAL, BUT ALSO ALLOWS FOR THE
8	SURVIVAL OF THE COMPANIES OR THE CONTINUANCE OF THE
9	COMPANI ES.

10 AND WE HAVE -- WHAT WE'VE DONE IN THIS 11 SPACE IS REALLY TO DRAW ACADEMICS TOGETHER WITH THE COMPANIES SO THE MAJORITY OF THE STUDIES THAT WE'RE 12 13 FUNDING IN THE TRANSLATIONAL AREA ARE ACTUALLY A COMBINATION OF ACADEMICS TOGETHER WITH COMPANIES. 14 AND IN THAT INTERSECTION, WE ARE LOOKING AFTER THE 15 INTERESTS FOR CALIFORNIA, THE ACADEMICS ARE LOOKING 16 17 AFTER THEIR INTERESTS AT UNIVERSITIES AND MEDICAL CENTERS, AND THE COMPANIES ARE TRYING TO LOOK AFTER 18 19 THEI RS.

20 SO WHAT WE'RE TRYING TO DO IS A SENSE OF 21 LET'S ALL GET TOGETHER AND MAKE THIS MORE EFFECTIVE, 22 AND THERE IS A CLIMATE OF WANTING TO DO THAT BECAUSE 23 IT'S NOT SO GOOD OUTSIDE THIS PARTNERSHIP. IT 24 ISN'T. IT'S MUCH BETTER TO BE IN IT AND TO ACCEPT 25 SOME OF THE --

75

1	MEMBER LOTT: I'M NOT ARGUING THAT POINT.
2	THAT MAKES ALL THE SENSE IN THE WORLD. HOW DO WE
3	ASSURE THE PUBLIC THAT WE REPRESENT THAT THERE ISN'T
4	ANYTHING BEING THAT WE'RE NOT COMPROMISING THE
5	GRANT-MAKING PROCESS, FOR EXAMPLE?
6	DR. TROUNSON: WELL, I THINK BEING
7	TRANSPARENT AND AS TRANSPARENT AS POSSIBLE. WE'RE
8	AS TRANSPARENT AS WE CAN BE. WE'RE CLEARLY HERE TO
9	ADDRESS YOUR QUESTIONS AS BEST WE CAN. WE ALLOW FOR
10	ALL THE PUBLIC DISCUSSION. ALL THE DECISIONS IN
11	THESE MATTERS ARE DONE AT OUR BOARD. AND I ASSURE
12	YOU THERE'S A LOT OF BLOGGING THAT GOES IN
13	ASSOCIATION WITH ALL THOSE DECISIONS. THEY'RE
14	BROADLY RECOGNIZED, AND THE SENSE MY OWN SENSE OF
15	IT IS THAT WE'VE GOT A VERY POSITIVE CLIMATE OF
16	WORKING TOGETHER.
17	NOW, WE KNOW WE ARE REQUIRED TO MEET THE
18	INTERESTS OF CALIFORNIA. THAT'S WHAT YOU DID IN
19	SETTING UP PROPOSITION 71. AND WE NEED TO MEET THAT
20	AS ABSOLUTELY BEST WE CAN, AND WE ARE ENDEAVORING TO
21	DO THAT. WE BELIEVE THAT THE BIGGEST BENEFIT THAT
22	YOU CAN PROVIDE FOR CALIFORNIANS IS IMPROVED
23	HEALTHCARE AND REDUCED HEALTHCARE COSTS. THAT HAS
24	BEEN THE NO. 1. BUT IF WE STIMULATE JOBS AND
25	INDUSTRIES, THAT WILL WORK TOO. THAT IS OKAY. AND

76

1	IF WE IMPROVE UNIVERSITIES AND OUR EDUCATION SYSTEMS
2	AND WE'RE RECOGNIZED AS WORLD LEADERS IN DOING THIS,
3	THAT WON'T HURT EITHER.
4	SO, NO. 1, WE WANT TO MAKE SURE WE DELIVER
5	AS BEST AS POSSIBLE THE TREATMENTS FOR THE PATIENT,
6	NO. 1 BENEFIT, BUT THEN THOSE OTHER BENEFITS ARE
7	WORTHWHILE ACHIEVING AS WELL.
8	MEMBER LIPSON: SO BASICALLY YOU' RE
9	CHANGING THE MAJOR FOCUS THAT WAS ENGENDERED IN
10	PROPOSITION 71. IN PROPOSITION 71 THE OPPONENTS
11	SAID THIS WOULD BE A WINDFALL FOR INDUSTRY. AND THE
12	RESPONSE WAS THAT 71 FOCUSES ON RESEARCH BY
13	NONPROFIT INSTITUTIONS, NOT CORPORATIONS. IT'S
14	SPECIFICALLY DESIGNED TO SUPPORT THE TYPE OF
15	BREAKTHROUGH RESEARCH CONDUCTED BY UNIVERSITIES,
16	MEDICAL SCHOOLS, HOSPITALS, AND OTHER NONPROFIT
17	INSTITUTIONS.
18	DR. TROUNSON: WELL, THAT IS STILL TRUE.
19	IF YOU ARE GOING TO TAKE A TREATMENT TO A CLINIC,
20	YOU NEED A LOT MORE MONEY THAN WE'VE GOT FOR EVERY
21	ONE OF THESE TREATMENTS. SO WE CAN ONLY GO IN THAT
22	PIPELINE AS FAR AS PHASE II. WE CAN'T GET BEYOND
23	THAT BECAUSE THE QUANTUM OF FINANCES REQUIRED IS WAY
24	BEYOND US. SO YOU HAVE TO ACTUALLY INTEGRATE WITH
25	THE DELIVERERS, WHETHER IT BE MEDICAL DELIVERERS,

77

-	
1	THE MEDICAL CENTERS, OR INDUSTRY. IF IT'S A SMALL
2	MOLECULE OR BIOLOGICAL, YOU'VE GOT TO INTEGRATE WITH
3	THEM. OTHERWISE IT'S NOT GOING TO GO. IT'S NO GOOD
4	US PUSHING DISCOVERY AND NOT GETTING IT TO GO TO THE
5	PATI ENTS.
6	SO THE COMPONENT PART IS TO TAKE THE
7	PATHWAY TO THE PATIENTS, WE HAVE TO INTERACT WITH
8	THEM. WE HAVE TO BECOME PARTNERS WITH THEM.
9	MEMBER LOTT: IT'S NOT THE GOAL. IT'S THE
10	PROCESS. IT'S THE STRUCTURE AND THE PROCESS THAT
11	NEEDS SOME CLARIFICATION.
12	DR. TROUNSON: OKAY. BUT I'M SAYING IS
13	THAT THE BROADER AIM OF PROPOSITION 71 WAS TO TAKE
14	THE DISCOVERIES AND TURN THEM INTO CURES. THE
15	BOTTOM LINE THAT THE PEOPLE UNDERSTOOD WAS THAT THEY
16	WOULD GET CURES FROM THIS. AND THERE WAS A
17	PROBABILITY THAT THESE DEVELOPMENTS, THESE
18	DISCOVERIES, WOULD PERCOLATE INTO CLINICAL
19	TREATMENTS WITH CURES.
20	MEMBER LOTT: I GOT TO TELL YOU, YOU AND I
21	ARE NOT ANYWHERE NEAR TALKING ABOUT THE SAME THING.
22	DR. TROUNSON: I'M SORRY. I WAS
23	ADDRESSING
24	MEMBER LOTT: WE'RE ASKING THE SAME
25	QUESTION. I'M TRYING TO FIGURE OUT WHY ARE YOU
	78
	,,,

1	TELLING ME ABOUT THE GOAL AND NOT ABOUT THE PROCESS.
2	DR. TROUNSON: WELL, THE PROCESS IS A
3	MATTER OF CREATING THE PARTNERSHIPS. AND SO WHILE
4	WE HAVEN'T LAID DOWN HOW WE'RE GOING TO DO THAT NOW
5	IN ENOUGH DETAIL, BECAUSE THAT'S PART OF THE PROCESS
6	THAT WE'RE GOING THROUGH, WHAT WE NEED TO DO TO BE
7	ABLE TO SIT DOWN AND CREATE A MORE COLLABORATIVE
8	COMPONENT. THIS IS WHAT THE EXTERNAL REVIEW WANTED
9	US TO DO, TO BE MORE CREATIVE. THIS IS THEIR I'M
10	RESPONDING TO THEIR RESPONSE. THEY WANT TO BE MORE
11	CREATIVE, MORE FACILITATIVE FOR INDUSTRY IN OUR
12	SECTOR. SO WE'VE GOT TO ACTUALLY LOOK AT WHAT WE
13	CAN DO WITH THEIR NEEDS TO ENABLE US TO MEET OUR
14	NEEDS AND THE NEEDS OF CALIFORNIANS.
15	SO IT IS A PROCESS, AND IT'S A PROCESS
16	SITTING DOWN AND WORKING OUR WAY THROUGH INDIVIDUAL,
17	MANY OF THE TIMES, NEGOTIATION.
18	MEMBER LOTT: HOW ARE YOU GOING TO DO THAT
19	WITHOUT TRIPPING OVER POTENTIAL CONFLICTS?
20	MEMBER KOVACH: LET ME USE AN EXAMPLE
21	PERHAPS, AT LEAST AS A WAY TO TRY TO FURTHER THE
22	DI SCUSSI ON.
23	MEMBER LOTT: PLEASE.
24	MEMBER KOVACH: AND IT WOULD BE PERHAPS IN
25	TRYING TO FACILITATE INTERACTIONS BETWEEN COMPANIES
	79

1	
1	AND ACADEMIC CENTERS THAT ARE FUNDED BY CIRM, THAT A
2	CONFLICT OR AN UNFAIR ADVANTAGE WOULD BE CREATED
3	AMONG A COMPANY THROUGH DISCUSSIONS THAT WERE
4	FACILITATED. AND ESSENTIALLY IT GOES, AS I'M
5	INTERPRETING IT, TO THE FACT THAT AN IDEA,
6	INTELLECTUAL PROPERTY, IS SOMETHING THAT CAN BE
7	TALKED ABOUT OVER A COFFEE TABLE. I THINK IT'S A
8	LEGITIMATE CONCERN; HOWEVER, THE REALITY IS THOSE
9	DISCUSSIONS HAVE TO TAKE PLACE. I THINK THE REASON
10	THAT IT COSTS SO MUCH TO DEVELOP A THERAPEUTIC IS
11	THE COMPLEXITY, ESPECIALLY WITH CELLS AS A DRUG.
12	THERE IS SO MANY DIFFERENT ASPECTS, THAT IT BECOMES
13	MUCH MORE COMPLEX THAN ONE COMPANY CAN HANDLE.
14	MY OWN FEELING IS A GOOD WAY TO ADDRESS
15	THAT IS THE AGE-OLD YOU DISCLOSE CONFLICTS. NO. 1,
16	YOU BASICALLY UP FRONT ORIENT YOURSELVES. AND THEN
17	THE SECOND THING THAT I WOULD ADVISE IS TO TRY TO
18	CREATE THE GROUND RULES UP FRONT THAT ESSENTIALLY
19	INCENTIVIZE FOR DISCLOSURE, MEANING A COMPANY, IT'S
20	GOT ITS OWN INTELLECTUAL PROPERTY AS WELL. AND SO
21	IT SHOULD WE SHOULD CREATE A FORUM TO WHERE
22	INFORMATION CAN BE EXCHANGED WITHOUT ANY EXPECTATION
23	OF PATENTS. IT'S LIKE THROW IT ALL IN THE POOL AND
24	DI SCUSS IT.
25	BECAUSE I THOUGHT ABOUT THIS A LOT.
	80

-	
1	THERE'S SO MUCH INNOVATION THAT NEEDS TO TAKE PLACE
2	LATER. THERE'S ALWAYS TIME FOR PATENT LATER. WHAT
3	WE TEND TO DO IS OVERPATENT, I THINK. THE COMPANIES
4	TEND TO OVERPATENT. JUST LIKE WE CAN EDUCATE OUR
5	ACADEMIC INVESTIGATORS, WE NEED TO EDUCATE THE
6	COMPANIES AS WELL, THAT THEY'RE JUST HURTING
7	THEMSELVES BY ALL THIS EARLY PATENTING.
8	AND SO TO DR. TROUNSON'S POINT, I THINK
9	THAT WHAT HE'S TALKING ABOUT IS CREATING AN
10	ENVIRONMENT THAT SOMEWHAT MIRRORS CONSORTIA IN OTHER
11	INDUSTRY. IT'S A CONSORTIUM THAT WE'RE TALKING
12	ABOUT. A PRECOMPETITIVE CONSORTIA THAT HAVE
13	OCCURRED IN OTHER INDUSTRIES, LIKE CHIPS. SEMATECH,
14	FOR EXAMPLE, IS A CONSORTIA. IT'S A PRECOMPETITIVE
15	CONSORTIA WHERE COMPETITORS FIGURE OUT, HEY, WE'RE
16	BETTER OFF TO SHARE INFORMATION PRECOMPETITIVELY.
17	SO I THINK THE WAY, IT'S ALMOST
18	PARADOXICAL, THE WAY TO ADDRESS IT IS TO MAKE SURE
19	YOU'RE TALKING AS MUCH AS POSSIBLE.
20	MEMBER LIPSON: LAST YEAR I BROUGHT UP
21	QUESTIONS WHICH WERE NEVER REALLY ANSWERED ABOUT HOW
22	DO YOU SELECT WHICH COMPANY TO WORK WITH? HOW DO
23	YOU YOU SELECT SOMEONE WHO GAVE MONEY TO GETTING
24	PROPOSITION 71 PUT ON THE BALLOT, OR DO YOU
25	SELECT

81

1	DR. TROUNSON: NO. NO. THEY HAVE TO WORK
2	THROUGH THE REVIEW PROCESS. THEY HAVE TO APPLY AS
3	IF THEY WERE AN INSTITUTION OF ANY KIND. SO WE
4	DON'T EXCEPT FOR TRAINING GRANTS AND SOME
5	SPECIFIC ACADEMIC GRANTS, LIKE THE LEADERSHIP
6	GRANTS, THE COMPANIES CAN COME INTO BASIC SCIENCE,
7	THEY CAN COME INTO TOOLS AND TECHNOLOGIES, AND
8	THEY'RE VERY INTERESTED IN TRANSLATION AND CLINICAL
9	WORK. SO THEY APPLY AS A UNIVERSITY WOULD.
10	WHAT WE'VE DONE, IN ORDER TO MAKE THESE
11	MORE EFFECTIVE, IS OFTEN TO GET THE ACADEMICS TO
12	WORK TOGETHER WITH COMPANIES BECAUSE ACADEMICS
13	HAVEN' T NECESSARI LY HAD A LOT OF EXPERIENCE OF
14	WORKING IN TRANSLATION AND EARLY CLINICAL WORK AND
15	COMPANIES HAVE. BUT YOU NEED THE DEPTH OF
16	INTELLIGENCE AND RESEARCH TO ACTUALLY FIGURE OUT HOW
17	TO DO THIS IN A VERY NEW AREA. SO THE COMBINATION
18	OF THE TWO IS PROVING VERY EFFECTIVE AT THE MOMENT.
19	NOW, YOU COULD COME IN AS ONLY A COMPANY,
20	OR YOU CAN COME IN AS ONLY AN ACADEMIC, BUT YOU
21	ACTUALLY ARE SUBJECT TO EXACTLY THE SAME
22	REQUIREMENTS AS IF YOU WERE APPLYING FROM A
23	UNI VERSI TY, EXACTLY.
24	MEMBER LIPSON: EXCEPT I GUESS, YOU KNOW,
25	ARE YOU GOING TO GIVE FAVORITISM TO CERTAIN
	82

Г

1	COMPANIES, OR HOW DO WE
2	DR. TROUNSON: NO FAVORITISM AT ALL. YOU
3	HAVE TO HAVE THE BEST APPLICANT AS JUDGED BY THE
4	GRANTS REVIEW TEAM, THE 15 SCIENTISTS DRAWN FROM
5	OUTSIDE CALIFORNIA SITTING TOGETHER WITH THE PATIENT
6	ADVOCATES, A GROUP OF PATIENT ADVOCATES OFF THE
7	BOARD. YOU HAVE TO UNDERGO THE REVIEW THAT'S
8	FOCUSED ON IS THIS THE BEST SCIENCE, IS THIS BEST
9	ADDRESSING THE REQUIREMENTS THAT WE LOOK FOR WHEN WE
10	ADVERTISE THE RFA, AND HAS THIS GOT THE BEST
11	OPPORTUNITY OF EITHER ACHIEVING THE BASIC SCIENCE
12	PROGRAM THAT THEY' VE PUT FORWARD OR THE
13	TRANSLATIONAL GET TO THE CLINIC. SO THEY HAVE TO
14	MEET THOSE CRITERIA AS IF THEY WERE ACADEMICS.
15	AND SOME COMPANIES HAVE PERFORMED BETTER.
16	SOME COMPANIES HAVE APPLIED I THINK THERE'S ONE
17	COMPANY TOLD ME THE OTHER DAY THEY APPLIED NINE
18	TIMES AND GOT ZERO GRANTS. SOME COMPANIES
19	WELL-KNOWN IN CALIFORNIA HAVE NEVER APPLIED, AND
20	THAT MAY CHANGE AS WE MOVE ALONG IN TIME. BUT THEY
21	APPLY AND WE FUND THEM IF THEY'VE GOT THE BEST WORK.
22	AND OFTEN, PARTICULARLY WHEN WE'RE WORKING TOWARDS
23	THE CLINIC IN TRANSLATION, THERE'S OFTEN A COMPANY
24	OR OFTEN SEVERAL COMPANIES ASSOCIATED WITH AN
25	ACADEMIC GROUP TO TAKE THAT PROGRAM THROUGH.

83

	DARKISTERS REFORTING SERVICE
1	MEMBER LOTT: HOW WILL THE ADVISORY PANEL
2	BE SELECTED, CONSTRUCTED, OPERATED?
3	DR. TROUNSON: I'M SORRY. I DIDN'T GET
4	THE FIRST.
5	MEMBER LOTT: THE ADVISORY, HOW WILL THAT
6	ADVISORY PANEL BE SELECTED, CONSTRUCTED, MANAGED,
7	ALL THAT KIND OF STUFF?
8	DR. TROUNSON: THE ADVISORY PANEL, WE'VE
9	APPOINTED A VICE PRESIDENT WHO'S REALLY BEEN
10	ELLEN FEIGAL IS HER NAME. SHE'S STARTING ON MONDAY.
11	SHE'S COME FROM AMGEN AS HER LAST APPOINTMENT, BUT
12	SHE'S IN ACADEMIA. SHE'S BEEN AT THE NATIONAL
13	CANCER INSTITUTE AT THE NIH. SHE'S ACTUALLY TAUGHT
14	FDA COURSES FOR UCSF. SHE DID HER PRIMARY WORK WITH
15	UCSD. WE'RE BRINGING HER ON BOARD, AND SHE'S GOING
16	TO DEVELOP THAT ADVI SORY BOARD.
17	SO THE ADVISORY BOARD THAT WE HAD IN MIND
18	WOULD NEED TO BE MADE UP OF PEOPLE WHO HAD EXPERTISE
19	IN A RANGE OF APPLICATIONS ACROSS THAT PRECLINICAL
20	AND CLINICAL PHASE. AND THERE WILL BE A GROUP OF
21	THOSE PEOPLE WHO HAVE REGULATORY EXPERIENCE AND
22	EXPERIENCE IN THOSE PARTICULAR AREAS THAT WE'RE
23	FUNDING WOULD BE AN EXTERNAL ADVISORY BOARD THAT
24	WOULD LOOK AT THE PROGRESS AND THE MILESTONES BEING
25	ACHIEVED BY THE TEAMS AND ALSO REVIEW THE GO/NO-GO

84

1	DECISIONS THAT WERE BUILT IN.
2	SO IF YOU CAN'T GET PAST THIS POINT,
3	YOU'RE UNLIKELY TO GET TO THE END OF YOUR PROGRAM IF
4	IT'S AN IND OR IF IT'S SOME OTHER THING. SO THAT
5	GROUP WILL BE APPOINTED BY ELLEN FEIGAL, WHO'S THE
6	NEW VICE PRESIDENT R&D. SHE COMES SHE'S GOT
7	STRONG EXPERIENCE IN THAT SECTOR. WE'VE GOT SOME
8	IDEA OF THE KIND OF PEOPLE THAT WE NEED, AND WE NEED
9	STRONG REGULATORY PEOPLE IN THAT GROUP. AND THEY
10	WILL BE FORMULATED AS AN ADVISORY GROUP TO GIVE US
11	ADVICE THAT WE CAN THEN PASS ON TO THE ICOC.
12	MEMBER LOTT: THESE PEOPLE WILL BE FREE OF
13	CONFLI CT?
14	DR. TROUNSON: YES, THEY WILL.
15	MEMBER LOTT: HOW WILL WE KNOW THAT?
16	DR. TROUNSON: WE WILL ENSURE THAT THEY' RE
17	NOT ASSOCIATED WITH ANY OF THE COMPANIES OR ANY OF
18	THE INSTITUTES THAT ARE INVOLVED IN THESE STUDIES.
19	AND IF THEY ARE, THEY CAN'T
20	MEMBER LOTT: THEY WILL BE ASKED TO DO
21	WHAT TO DEMONSTRATE THAT?
22	DR. TROUNSON: THEY'LL BE REQUIRED TO DO
23	ALL OF THE CONFLICTS ASSESSMENTS THAT WE WOULD DO
24	INTERNALLY AND ON THE GRANTS WORKING GROUP. SO THEY
25	NEED TO IDENTIFY WHETHER THEY HAVE AN ECONOMIC OR A
	85

1	WORKING RELATIONSHIP OR A RECENT PAST HISTORY OF ANY
2	PARTICULAR ORGANIZATION THAT'S BEING ASSESSED,
3	INCLUDING THE UNIVERSITY INSTITUTION.
4	MEMBER LIPSON: I THINK WHAT WE'RE ALL
5	SAYING HERE IS YOU NEED TO PUT SOME BONES TOGETHER
6	FIRST. WE'RE HEARING GENERALITIES RATHER THAN WHAT
7	IS BEING DONE SPECIFICALLY TO MAKE CERTAIN WE DON'T
8	HAVE CONFLICTS AND MAKE CERTAIN THINGS ARE DONE IN A
9	CONSISTENT MANNER. AND I'M HEARING I UNDERSTAND
10	WHAT YOU ARE SAYING, BUT YOU'RE NOT REALLY ANSWERING
11	THE QUESTION IN AN ORGANIZED WAY, I GUESS.
12	DR. TROUNSON: I APOLOGIZE FOR BEING
13	DISORGANIZED IN ANSWERING YOUR QUESTION. I GUESS
14	I'M NOT UNDERSTANDING IT WELL ENOUGH, AND I
15	APOLOGIZE FOR THAT. BUT SINCE SOME OF THESE
16	ACTIVITIES WE HAVEN'T DONE YET, BUT THEY WILL HAVE
17	TO FOLLOW ALL OUR CONFLICT OF INTEREST POLICIES FOR
18	ANY ORGANIZATION THAT GIVES US THOSE KIND OF ADVICE.
19	MEMBER LIPSON: RIGHT. BUT THERE'S A
20	PROBLEM ALSO IN THAT IT'S A SMALL FIELD AND PEOPLE
21	KNOW PEOPLE. AND SO THERE ARE WAYS THAT PEOPLE CAN
22	HAVE INFLUENCE AND IGNORE CONFLICT OF INTEREST
23	SITUATIONS TO HELP A BUDDY.
24	MR. HARRISON: CAN I JUST RESPOND TO THE
25	CONFLICT QUESTION DIRECTLY WITH RESPECT TO OUR GRANT
	07
	86

1	AND LOAN-MAKING PROCESS? FROM THE BOARD'S
2	PERSPECTIVE, IT IS BLIND. BOARD MEMBERS ARE
3	PRESENTED WITH AN APPLICATION NUMBER. THE IDENTITY
4	OF THE APPLICANT, WHETHER A COMPANY OR A UNIVERSITY,
5	IS NOT KNOWN TO THE BOARD MEMBERS. IN ADVANCE OF
6	EACH MEETING, WE SEND A LIST TO EACH MEMBER OF THE
7	BOARD WITH EACH OF THE ENTITIES WHO HAS A FINANCIAL
8	INTEREST IN AN APPLICATION. IT'S DISAGGREGATED FROM
9	ANY APPLICATION NUMBER. BOARD MEMBERS CHECK THE
10	BOXES NEXT TO ANY ENTITY, WHETHER IT'S A COMPANY OR
11	A UNIVERSITY, IN WHICH THEY HAVE A FINANCIAL
12	INTEREST. WE THEN PROVIDE THEM, AFTER REVIEWING IT,
13	WITH A LIST OF APPLICATIONS IN WHICH THEY CANNOT
14	PARTI CI PATE.
15	AND WHEN DECISIONS ARE MADE ON A
16	PARTICULAR APPLICATION OR APPLICATIONS, THEY'RE MADE
17	BLIND BY THE BOARD. AND THOSE MEMBERS WHO HAVE AN
18	INTEREST ARE PRECLUDED FROM PARTICIPATING IN THAT
19	DECISION. THAT'S OUR CURRENT GRANT-MAKING PROCESS.
20	WITH RESPECT TO THE QUESTIONS YOU' VE ASKED
21	ABOUT THE PROCESS THAT DR. TROUNSON IS DESCRIBING,
22	THIS PROCESS IS NOT IN PLACE YET. THIS IS A
23	RESPONSE TO AN EXTERNAL ADVISORY REPORT THAT
24	LITERALLY JUST CAME DOWN AT THE END OF THIS PAST
25	YEAR.

87

1	AS WE PUT TOGETHER THE PROCESS FOR
2	IMPLEMENTING THE EXTERNAL ADVISORY PANEL'S
3	RECOMMENDATIONS, WE WILL TAKE INTO ACCOUNT ISSUES
4	LIKE CONFLICT OF INTEREST, LIKE YOU IDENTIFIED, IN
5	AN EFFORT TO ENSURE THAT WE ARE COMPLETELY
6	TRANSPARENT AND THAT WE PREVENT ALL CONFLICTS OF
7	INTEREST.
8	BUT YOU' RE RIGHT TO THE EXTENT THAT WE
9	HAVEN'T PUT THOSE BONES TOGETHER YET BECAUSE WE'RE
10	JUST NOW IN THE PROCESS OF EVALUATING THE REPORT AND
11	DECIDING HOW TO PROCEED.
12	MEMBER LIPSON: I ASKED A SIMILAR QUESTION
13	LAST YEAR.
14	MR. HARRISON: I TRIED AS BEST AS I COULD
15	TO ANSWER THEM.
16	MEMBER LIPSON: THERE'S BEEN REALLY NO
17	MOVEMENT HERE. CONSIDERING WORKING WITH INDUSTRY,
18	YOU HAVE TO BE PREPARED TO WORK WITH INDUSTRY AND
19	HAVE BASIC GUIDELINES IN PLACE. AND THEN YOU CAN
20	WORK WITH EACH INDIVIDUAL COMPANY THAT IS
21	MERI TORI OUS.
22	MR. HARRISON: WE DO. COMPANIES APPLY IN
23	THE SAME WAY THAT UNIVERSITIES DO, BLIND. SO
24	MEMBERS OF THE BOARD, WHEN THEY MAKE DECISIONS ABOUT
25	FUNDING AN APPLICATION FROM THE COMPANY, DON'T KNOW
	88

1	WHETHER IT'S FROM A COMPANY OR A UNIVERSITY.
2	THEY'RE MAKING DECISIONS BASED ON THE MERITS OF THE
3	SCIENCE AND THE RECOMMENDATIONS OF THE GRANTS
4	WORKING GROUP. SO WE DO HAVE A PROCESS IN PLACE,
5	AND I THINK IT'S WORKED VERY WELL.
6	DR. TROUNSON: OKAY. I THINK WE CAN
7	PROBABLY GO TO THE NEXT ONE.
8	THE INTERNATIONAL PARTNERSHIPS, WE HAVE
9	COLLABORATIVE FUNDING ARRANGEMENTS WITH NINE
10	COUNTRIES, WE'VE ADDED INDIA JUST RECENTLY, WHERE WE
11	WORK TOGETHER WITH THOSE COUNTRIES. WHAT HAPPENS IN
12	THOSE PARTICULAR INSTANCES IS THE COUNTRY THAT WOULD
13	HAVE A SCIENTIFIC GROUP THAT WANTS TO WORK WITH A
14	CALIFORNIA GROUP, THEY APPLY TOGETHER IN A SINGLE
15	GRANT APPLI CATI ON.
16	IF THAT MAKES ITS WAY THROUGH THE SYSTEM
17	AND IS AWARDED AFTER GRANTS REVIEW AND AWARDED BY
18	THE ICOC, WE PAY FOR THE IN-CALIFORNIA COMPONENT OF
19	THE GRANT AND THE UK OR JAPAN PAYS THE
20	OUT-OF-CALIFORNIA COMPONENT SO THAT THE GROUPS ARE
21	WORKING TOGETHER, BUT THEY'RE FUNDED IN ONE PROJECT,
22	BUT THEY'RE FUNDED SEPARATELY BY THE
23	OUT-OF-CALIFORNIA AND WE PAY FOR THE IN-CALIFORNIA
24	COMPONENT. AND THAT, I HAVE TO SAY, IS WORKING
25	EXTREMELY WELL TODAY. THE PROJECTS ESSENTIALLY THAT

89

1	BRINGS NOW SOME OF THE BEST PEOPLE IN THE WORLD NOW
2	WORKING TOGETHER WITH THE CALIFORNIANS. AND WE'RE
3	NOW MAKING SOME ARRANGEMENTS WITH THE NIH TO BE ABLE
4	TO WORK TOGETHER WITH THE NATIONAL INSTITUTES OF
5	HEALTH IN THE SAME KIND OF WAY.
6	SO THIS PROGRAM THEY WANT US TO EXPAND BY
7	IDENTIFYING EXCELLENCE, MISSING CAPACITY THAT MAY BE
8	NOT HERE IN CALIFORNIA, FIND THE RAPID DEVELOPMENTS
9	AND THE INTEREST TO COLLABORATE WITH CALIFORNIANS,
10	PERHAPS MAKE MULTIPLE INTERNATIONAL/INTERSTATE
11	PARTNERSHIPS. THEY' VE BEEN ONE TO ONE SO FAR, BUT
12	YOU COULD DO MULTIPLE ARRANGEMENTS, SAY, WORK WITH
13	TWO COUNTRIES OR TWO STATES.
14	EXPLORE INTERNATIONAL INDUSTRY
15	PARTNERSHIPS THAT CAN ACCELERATE THE CLINICAL
16	THERAPIES BECAUSE SOMETIMES YOU GET AN ACCELERANT
17	HAPPENING AND ACCELERATION IN ONE PLACE THAT'S NOT
18	CALIFORNIA. IT WOULD BE NICE TO PICK THAT UP AND
19	MATCH IT BACK WITH CALIFORNIA AND GET OURS TO SORT
20	OF TRAVEL AT THE SAME RATE OR ACCELERATE AS WELL AND
21	CONNECTING PARTNERS WITH THE NIH.
22	SO THEY FELT THAT THIS WAS A STRONG
23	PROGRAM. CURRENTLY \$58 MILLION HAS BEEN PUT INTO
24	THE PROGRAM BY THE COLLABORATIVE FUNDING PARTNERS
25	INTO COMPANY PROJECTS. SO IT WILL EXPAND, BUT DOES
	90

1	TAKE SOME MANAGEMENT TO MAKE SURE EVERYTHING WORKS
2	WELL. BUT FOR THE SCIENTIFIC POINT OF VIEW, THESE
3	PROJECTS HAVE REALLY TAKEN OFF, THOSE COLLABORATIVE
4	FUNDING PROJECTS HAVE REALLY SORT OF TAKEN OFF VERY
5	RAPI DLY.
6	OUTREACH AND EDUCATION, I THINK THERE'S
7	BEEN A LOT OF DISCUSSION OF THIS. I'M NOT SURE WE
8	NEED MORE. THEY DID IDENTIFY A NEED TO INCREASE THE
9	QUALITY AND THE BREADTH OF COMMUNITY OUTREACH. I
10	THINK WE'VE DEALT WITH THAT PRETTY MUCH IN EARLIER
11	DI SCUSSI ON.
12	GOVERNANCE ISSUES, I THINK THAT WAS ALSO
13	BROUGHT UP. REEXAMINE THE ROLE OF THE I COC AND
14	PRESIDENT AND MANAGEMENT IN DELIVERY OF THE STAGE II
15	CIRM PROGRAM BASICALLY TO ENHANCE THE EFFECTIVENESS
16	OF THE PROGRAM. SO I'M INTERESTED IN MAKING THIS
17	PROGRAM WORK BETTER, MORE EFFICIENTLY, MORE
18	EFFECTIVELY, AND UTILIZING THE EXPERIENCE THAT
19	EXISTS ON THE BOARD AND IN THE CHAIR AND THE VICE
20	CHAIRS TO THE BENEFIT OF THE AGENCY. AND SO I'LL BE
21	PUSHING TO MAKE THIS AS EFFECTIVE AS I CAN, BUT IT
22	WILL BE LIMITED TO WHAT THE BOARD AGREES TO IN THIS
23	RESPECT.
24	THERE WERE SEVERAL OTHER ISSUES BEING LESS
25	CONCERNED BY PROCESS DOCUMENTATION, MORE FLEXIBLE
	91

1	FOR ENHANCED OUTCOMES. ANY ORGANIZATION CAN BE
2	THOUGHT TO BECOME BUREAUCRATIC IN TIME. IT'S A BIT
3	OF EFFORT TO STOP THAT BECAUSE IF YOU ARE GOING TO
4	BE INNOVATIVE, YOU DON'T NEED TO BE BUREAUCRATIC.
5	IT DOESN'T WORK SO WELL HAND IN HAND.
6	AND THE MANAGEMENT, FROM THEIR POINT OF
7	VIEW, WAS WAY TOP LEAN TO DEVELOP FOR REALLY
8	GETTING DELIVERY OF THE OPPORTUNITY. THEY FELT THAT
9	WE'RE WAY TOO LEAN FOR DOING THAT. AND WE SAID THAT
10	WE WILL TRY WE WERE GOING TO INCREASE, INCREASE
11	THE NUMBER OF SCIENTIFIC STAFF BECAUSE WE ACTUALLY
12	FEED BACK ON OUR PROJECTS. THE NIH DOES NOT FEED
13	BACK ON THE PROJECTS, NOR DO MANY OF THE RESEARCH
14	FOUNDATIONS. SO WHEN WE GET QUARTERLY REPORTS OR
15	YEARLY REPORTS, WE'RE FEEDING BACK TO THOSE
16	SCIENTISTS, SAYING, HEY, THAT'S NOT WHAT YOU REALLY
17	AGREED TO, OR FANTASTIC. YOU'VE ACCELERATED. I
18	THINK JIM HAS BEEN PART OF THAT IN THE PAST AND SEEN
19	THAT WE HAVE A ONE-TO-ONE ON THE SCIENTISTS.
20	AND IF IT'S A COMPANY, WE ARE MAKING SURE
21	THAT THEY ARE MEETING THOSE KIND OF DEADLINES THAT
22	THEY PUT IN. THAT DOES NOT HAPPEN WITH NIH, NOR
23	WITH MANY OF THE OTHER FUNDING BODIES. WE WANT IT
24	TO HAPPEN. WE'RE HERE FOR A RELATIVELY SHORT TIME.
25	MAYBE THEY'RE THERE FOREVER, BUT WE WANT THESE

92

1	DOLLARS TO WORK AS EFFECTIVELY AS POSSIBLE.
2	SO WE HAVE STOPPED SOME PROJECTS. WE'VE
3	ACTUALLY TERMINATED THEM BECAUSE THEY DIDN'T DO WHAT
4	THEY AGREED TO DO. IT'S NEVER HAPPENED WITH AN NIH
5	PROJECT. AND YOU CAN IMAGINE SOME OF THE SENIOR
6	SCIENTISTS IN CALIFORNIA BEING TOLD YOU DIDN'T DO
7	WHAT YOU SAID YOU WERE GOING TO DO, AND WE'RE GOING
8	TO TAKE YOUR GRANT AWAY BECAUSE WE'VE GIVEN YOU A
9	COUPLE OF OPPORTUNITIES TO CORRECT THAT, BUT YOU
10	DIDN'T. AND THAT HAS HAPPENED. SO WE ARE DIFFERENT
11	IN THAT RESPECT.
12	AND SO I THINK WE'VE DONE A TERRIFIC JOB,
13	BUT WE'RE PRETTY LEAN. WE CAN ONLY EXPAND TO STAY
14	UNDER THAT 6-PERCENT BAR NO MATTER WHAT WE DO, AND
15	WE'RE GOING TO STAY WELL UNDER THAT AS LONG AS I'M
16	THERE.
17	I THINK THAT'S PRETTY MUCH IT. IS THERE
18	ANYTHING? I THINK THESE WERE THE MAJOR
19	IMPLICATIONS, AND WE'VE KIND OF DISCUSSED THOSE AS
20	WE PASSED THROUGH. SO I'M HAPPY TO TAKE FURTHER
21	QUESTIONS AND APOLOGIZE FOR NOT GETTING SHARPLY TO
22	THE POINT THAT HAS BEEN ASKED BY SOME OF THE
23	MEMBERS.
24	CHAIRMAN CHIANG: ANY OTHER QUESTIONS?
25	ITEM 9 WAS COVERED IN THE INITIAL
	93


1	COMMENTS. SO LET'S GO TO ITEM 10, CONSIDERATION OF
2	THE DRAFT AGENDA FOR THE NEXT MEETING. DOES ANYBODY
3	HAVE ANYTHING ELSE THEY WANT ADDED TO THE AGENDA?
4	MEMBER SADANA: I FEEL WE SHOULD GET A
5	SUMMARY OF AT LEAST WHAT PROGRESS HAS BEEN IN ANY OF
6	THE INSTITUTIONS WHICH ARE YOU KNOW, THIS IS
7	TAXPAYERS' MONEY AND STATE MONEY WHICH IS BEING
8	UTILIZED. WHAT RESULTS HAVE ANY OF THESE THINGS
9	SHOWN? IS THERE ANY POTENTIAL? YOU DON'T HAVE TO
10	DISCLOSE ABOUT ANYTHING BECAUSE THERE MAY BE A
11	PRIVACY ISSUE OR LOSS OF INTELLECTUAL PROPERTY, BUT
12	WE NEED THOUGH WE'RE NOT A BODY WHICH IS
13	CONCERNED WITH THAT, IT WOULD BE NICE, AT LEAST, TO
14	BE SUMMARIZED.
15	DR. TROUNSON: I CAN GIVE YOU THE REPORT
16	THAT WE PROVIDED TO THE EXTERNAL REVIEW, WHICH HAD
17	EXACTLY WHAT YOU ARE SAYING IN. IF YOU WOULD
18	IT'S GOT A LOT OF APPENDICES, BUT WE CAN PROVIDE
19	THAT. IT IS ON THE WEBSITE, BUT WE CAN PROVIDE IT
20	TO YOU, AND IT DOES LIST THOSE DEVELOPMENTS. I
21	HAVEN'T TRIED TO DO THAT THIS TIME, BUT WE CAN DO
22	THAT CLEARLY IF YOU WISH.
23	MEMBER LOTT: I SERVE ON A NUMBER OF OTHER
24	BOARDS, AND ONE OF THE THINGS THAT'S VERY HELPFUL
25	FOR US, IN LINE WITH WHAT MY FELLOW MEMBER IS
	94

1	SAYING, WE GET A DASHBOARD OF KEY METRICS THAT SHOWS
2	PROGRESS OVER A PERIOD OF TIME. THAT'S REAL EASY
3	FOR US LAYPEOPLE TO FOLLOW. A DASHBOARD OF KEY
4	METRICS WOULD BE WONDERFUL.
5	DR. TROUNSON: I HAVE A SLIDE, NOT HERE,
6	BUT I HAVE A SLIDE I CAN PROVIDE THAT AS WELL, WHICH
7	IS ON ONE SLIDE WHICH GIVES THE KEY ACHIEVEMENTS,
8	WHICH INCLUDE THE CLINICAL TRIALS THAT ARE GOING,
9	THE NUMBER OF GRANTS, THE KEY BITS, THE NUMBER OF
10	PUBLICATIONS THAT HAVE COME OUT WITH OUR BANNER ON
11	IT. 23 PERCENT OF THOSE ARE IN THE HIGH IMPACT
12	JOURNALS. ALL OF THE PARAMETERS SOME OF THE
13	PARAMETERS YOU'RE SEEING ARE ON ONE SLIDE, I CAN GET
14	THAT FOR YOU, AND THEN I'LL ALSO MAKE SURE THAT YOU
15	CAN GET THE REPORT THAT I PROVIDED TO THE EXTERNAL
16	REVIEW, WHICH REALLY HAS A LOT OF DETAIL, BUT IT'S
17	SUMMARIZED. IT'S IN LAY FORM. IT'S NOT DETAILED
18	HEAVY READING, BUT IT'S GOT ALL OF THE KIND OF
19	THINGS THAT YOU ARE SEEKING.
20	BUT NEXT TIME WE COME, PERHAPS WE CAN MAKE
21	SURE THAT WE PROVIDE SOMETHING LIKE THAT, WHICH
22	WOULD BE HELPFUL.
23	MEMBER LIPSON: COULD WE GET THAT SOONER
24	THAN LATER? WE GOT YOUR NOTEBOOK AS WE CAME IN.
25	DR. TROUNSON: I KNOW, BUT WE WERE
	95

1	REQUESTED TO DO IT THAT WAY. YOU LET US KNOW WHEN
2	YOU WANT IT. WE DID ASK AND THEY SAID BRING IT
3	ALONG. WE WILL DO IT, WE WILL GET IT IN AN EARLIER
4	FORM. WE'LL WORK WITH RUTH TO MAKE SURE THAT WE GET
5	IT IN THE TIME THAT YOU REQUIRE. I'LL HAVE STAFF
6	MAKE SURE WE DO THAT.
7	CHAIRMAN CHIANG: IT'S DULY NOTED. IT
8	WILL BE ON THE AGENDA. IT WAS ACTUALLY ON THE
9	AGENDA FOR ITEM NO. 7 THIS TIME. WE'LL MAKE SURE WE
10	HAVE SUFFICIENT DETAILS TO SATISFY THE MEMBERS.
11	PUBLIC COMMENT. ANYONE WISH TO MAKE
12	COMMENT?
13	ITEM 12, BOARD MEMBER TIME. ANY REMAINING
14	I TEMS?
15	MEMBER SADANA: THE ONLY OTHER THING I'D
16	LIKE TO BRING UP IS AS CIRM IS NOW INVOLVED WITH A
17	LOT OF INSTITUTIONS WHICH HAVE OUT-OF-STATE OR
18	OUT-OF-COUNTRY CONNECTIONS AND IF SOMETHING IS
19	ACHIEVED BY YOU OR BY THESE INSTITUTIONS, HOW DO YOU
20	PROTECT INTELLECTUAL PROPERTY NOT BEING GETTING
21	OUT OF THE STATE?
22	DR. TROUNSON: IF WE CAN ADDRESS THAT
23	PERHAPS NEXT TIME, WE WOULD DO THAT. I'LL MAKE SURE
24	GENERAL COUNSEL COMES WITH US THE NEXT TIME. SHE'S
25	RESPONSIBLE FOR THOSE ARRANGEMENTS. AND I THINK SHE
	07
	96

_	BARRISTERS REFORTING SERVICE
1	MIGHT BE ABLE TO ADDRESS YOUR QUESTIONS MORE
2	EMPHATICALLY THAN PERHAPS I CAN, BUT SHE TAKES A
3	HEAVY RESPONSIBILITY IN THOSE AREAS TO PROTECT THE
4	INTELLECTUAL PROPERTY OF OUR INTERESTS IN ALL THESE
5	ARRANGEMENTS.
6	CHAIRMAN CHIANG: NEXT MEETING OR DO YOU
7	WANT A RESPONSE SOONER THAN THAT?
8	MEMBER SADANA: SURE. THAT WOULD BE FINE.
9	CHAIRMAN CHIANG: WITH THAT, WE ARE
10	ADJOURNED. THANK YOU ALL.
11	(THE MEETING WAS THEN ADJOURNED AT
12	4:13 P.M.)
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	97
ļ	71
	1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626

1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM



I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE CITIZEN'S FINANCIAL ACCOUNTABILITY OVERSIGHT COMMITTEE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

> METROPOLI TAN WATER DI STRICT 700 N. ALAMEDA STREET LOS ANGELES, CALI FORNI A ON FRI DAY, JANUARY 28, 2011

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100

98